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ABSTRACT
As cartilage tissue has limited repair capacities, tissue engineering has emerged as a
promising alternative for cartilage repair. The scaffold is a primary component of the tissue
engineerig design, yet little inormation exists regarding the effects of polymer and scaffold
properties on tissue growth. In this study, we have developed a novel scaffold, PLG
micro spheres, for use in cartilage tissue engineerig, which has the capacity for alterations in
polymer and scaffold. We examed the effects of molecular weight, hydrophobic capping,
delivery ofMg(OHh microsphere size, and controlled release oflGF-I. Our fmdings
demonstrated that polymer parameters distinctively affect tissue and matrx output.
Specifcally, micro spheres with high molecular weight polymer produced tissue with high
GAG content and tissue mass in vivo and in vitro, while micro spheres with capped polymer
induced steady tissue and matrx accumulation, but may have precluded cell attachment.
Release of buffer to the growing cartilage had negative effects on tissue formation in vivo
and in vitro. Additionally, increasing microsphere diameter generated more samples with
center of necrotic tissue. The presence of micro spheres induced greater carlage mass and
matrx content than cartilage from cells alone. Delivery oflGF-I induced a dose-dependent
effect on matrx and tissue production in vivo, with the highest effective load oflGF-I (0.3%)
generating the most matrx and tissue accumulation. In contrast, the in vitro IGF-I dose-
dependent effect induced on matrix and tissue production peaked at a dose of 0.02% IGF-
with higher doses generating less tissue and matrx. Taken together, changes in polymer or
scaffold composition and release of growth factor can be optimzed to form carilage with
enhanced tissue parameters. Moreover, these results demonstrate a novel scaffold with
potential to support carilage regeneration and provide simultaneous drug delivery.
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CHAPTER I
INTRODUCTION
Cartilage Biology and Homeostasis
Hyaline carilage is one of four cartilage classes found in the body, and articular
cartilage is the tye of hyaline cartilage found in synovial joints (Figure lA). Articular
cartilage is unique from other tissues in the body in that it lacks vascularity, nerves, and
lymphatic vessels. Cartilage tissue is fuher distinguished by its ability to exist in low
oxygen tensions , 1 and thus cellular energy requirements must be fulfilled by alternative
methods. At its surface, cartilage tissue fulfills these energy needs by diffsion of
nutrients from synovial fluid; while deeper in the tissue the chondrocytes use glycolysis
to generate energy.2 These metabolic processes enable chondrocytes, the fuctional cell
of cartilage tissue, to synthesize and maintain the extracellular matrix (ECM) of articular
cartilage.
The ECM (Figure IB , C), making up only 20-40% of the total tissue wet weight
consists of a network of collagen, proteoglycan, and non-collagenous proteins, molecules
that provide the major tissue fuctions of resistance to mechanical loading, stress
distribution and joint lubrication. The collagen molecules comprise 50-80% of cartilage
dry weight 4 and although multiple tyes of collagen molecules are found in the ECM
type n collagen accounts for almost 90%.5 Collagen fibrils of varying tyes form
collagenous networks that can contact the cell via surface receptors such as integrins , and
f';
these interactions of cells with the ECM are necessary for tissue organization and
maintenance since disruption of collagen-cell contacts can induce apoptosis. Although
collagen networks manifest throughout the tissue, organization of collagen molecules
varies with depth (Figure IB). At the articulating surface, collagen molecules are
oriented parallel to the surface, enabling stress to be distributed throughout the tissue and
protecting the tissue against tensile and shear stresses. In the middle and deep zones of
the tissue, collagen molecules respectively orient randomly and perpendicularly, and
serve to entrap and cluster aggregating proteoglycan molecules.
Proteoglycan molecules consist of a core protein and multiple covalently bound
sulfated glycosamioglycan (GAG) moieties and comprise 25-35% of cartilage dry
weight.2 The sulfated GAGs give proteoglycans a high negative charge that hydrates the
tissue, and subsequently, the high water content brings cationic charge balance.2 Thus
the negatively charged proteoglycan molecules entrapped within a collagen network
provide for resistance to compressive strains on the tissue.
Proteoglycans can be divided into two main categories - large aggregating
proteoglycans and small proteoglycans. Aggrecan is a large aggregating proteoglycan
that is considered to be a hallmark for cartilage tissue. It consists of a core protein with
multiple chondroitin-sulfate and keratin-sulfate side chains. Aggrecan binds to
hyaluronan in the ECM via lin protein, and this tripartite complex can pack densely
between collagen molecules or interact with the chondrocyte indirectly by binding to
CD44 or hyaluronan (HA) synthase on the cell surface.
Unlike collagen whose half-life is extensive, aggrecan and other proteoglycans
have high turnover 7 and this turnover ofECM is regulated by chondrocytes. In mature
cartilage , chondrocytes actively engage in matrix remodeling, and although remodeling
remains poorly understood, responses to mechanical loading, injur or disease are some
events that induce matrix remodeling. 10 Chondrocytes respond to these signals for
remodeling by synthesizing catabolic enzymes in response to cytokines, such as
interleukin-I (IL- l), that degrade matrix molecules , or making stimulatory cytokines
such as insulin-like growth factor-I (IGF-I) and transforming growth factor- (TGF-
that signal for chondrocytes to produce and rebuild the ECM.
This seemingly simplified matrix remodeling of catabolic and anabolic activities
is a response to complex communication within the tissue. As chondrocytes make up
only 2- 10% of the tissue , dependent on organism, and do not maintain cell-cell
interaction, signals from the ECM or cytokines are sent through receptors on the
chondrocyte surface. For instance, chondrocytes have been shown to have numerous
integrin clusters on the cells surface, including a1 I, a2 1, all l, which bind to collagen
tye II and VI. These integrins form focal adhesions with matrix molecules of the
tissue and these focal adhesion complexes can also be a prerequisite for chondrocyte
responsiveness to growth factors , such as IGF- 167 Other surface receptors , including
annexin V, anchorin CII or CD44 , also form contacts with ECM molecules, such as
collagen tye II or HA. Some of these interactions have been shown to modulate matrix
homeostasis, and the importance of these interactions can be crucial, as blocking of CD-
44 and HA binding can lead to matrix degradation. 
Additionally, cartilage structure and function can lead to severe limitations in
endogenous cartilage repair. Due to limitations of blood flow and molecule diffusion
through a dense ECM, lesions or defects caused by trauma or severe damage from
diseases such as osteoarthritis cannot easily be repaired by endogenous pathways.
Furher, the limited repair that occasionally occurs does not integrate well with existing
cartilage tissue. Thus , alternative methods to facilitate cartilage healing have been
actively explored. Most recently, tissue engineerig has become a promising option for
::j
cartilage repair.
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Cartlage Tissue Engineering and Repair
Because tissue engineering may provide an alternative method for cartilage repair
numerous strategies have been evaluated for cartilage regeneration, including approaches
using only chondrocytes, seeding cells on polymer scaffolds , and delivering growth
factors to the system.
Cartilage Regeneration with Chondrocytes
In its simplest form, neo-tissue generation can occur using only chondrocytes, but
chondrocyte dedifferentiation presents one caveat to cartilage tissue formation by only
cells. When chondrocytes are grown in monolayer cultures in vitro they tend to
dedifferentiate, and in fact, chondrocytes have been shown to lose their tye n collagen
expression and instead synthesize tye I collagen, a marker for dedifferentiation and
fibrous-like tissue. 13 14 Similarly, the normal spheroidal shape ofthe chondrocyte is lost
to a more spindle-shaped cell.
The dedifferentiation events of monolayer culture can be circumvented by other
tyes of in vitro culture. Chondrocytes can be maintained as pellets in suspension
culture. Using these culture conditions chondrocytes have been shown to deposit a
matrix of collagen tye IT and tyical cartilage proteoglycans. 17 In addition
chondrocytes retain their three-dimensional rounded morphology. In addition, the
development of other 3-dimensional culture conditions have been used to maintain
chondrocyte phenotye and matrix molecule production. Specifically, the use of
materials such as alginate18 or agarose13 can be used to maintain cell populations.
Recently, a method of using chondrocytes cultured in alginate beads, referred to as
alginate-recovered chondrocyte (ARC), has been used to engineer cartilage. 19 In the
ARC culture system, chondrocytes are cultured in alginate to re-establish the
proteoglycan-rich cell associated matrix, and after this matrix restoration, the cells have
been seeded onto tissue cultue inserts and have been shown to form cartilaginous
tissue. 19 Unfortunately one drawback to these cell only techniques is the hypercellularity
and lack of appropriate cell spacing associated with the tissue. 17
Use of Polymer Scaffolds in Cartilage Tissue Engineering
Because of the drawbacks of cell culture methods, much of tissue engineering has
focused on the use of a scaffold. As an integral dimension of the design, scaffolds have
ranged from polymers that can be shaped to those that can be injected or molded. 
shaped scaffold, such as fibers20 and sponges 21 provide a pre-defined volume and shape
that the growing tissue can take. These applications have been used with various
polymers, but polylactic acid (PLA), polyglycolic acid (PGA), or their copolymers (PLG)
(Figure 2) have desirable characteristics such as biocompatibility and biodegrability,
making them widely used to fabricate scaffolds for various tissue engineering
applications. Typically, as ECM is formed and deposited onto the scaffold, the polymer
degrades , and this degradation and matrix deposition has been correlated to many
systems using mathematical models based on product inibition feedback. 22 Another
beneficial facet of using PLG type scaffolds is the ease of polymer manipulation;
properties such as polymer degradation or cell attchment can be easily modified by
changes in polymer chemistry or scaffold production
Unfortunately, the drawback to such shaped scaffolds is the invasive procedure of
implantation, as these scaffolds must be surgically inserted in the recipient. A less
invasive scaffold has been found in polymers that can be injected, such as fibrin
photopolymerizing gels25 or hydrogels?6 In some cases, these tyes of scaffolds have
been directly injected into the wound site and have been shown to mediate repair,27 but
these scaffolds could also be molded into specific shapes in vitro 26 which can then be
surgically implanted in vivo.28 While the appeal of these scaffolds is their versatile use
and non-invasive nature, these scaffolds cannot be readily manipulated to change
characteristics such as degradation rate.
Thus, because no category of polymer scaffolds for tissue engineering fit all
desirable criteria, many continue to be extensively manipulated and studied for optimal
usage. Exploration of polymer scaffolds for tissue engineering has been demonstrated
both in vitro and in vivo. Evaluation in the in vitro environment is amenable to external
controls with ease of repetition of culture conditions, as a known amount of growth
factor, stress, and strain can be consistently delivered and monitored. Similarly, the
effects of these conditions are easier to assess, since the environment is controlled and
not coupied to endogenous host factors. As such, polymer scaffolds have been seeded
with chondrocytes and growth factors 29-31 or subjected to mechanicalloading 35 and
incubated in vitro , exhibiting varying levels of tissue growth, matrix molecules and
stimulation of cell proliferation.
Although in vitro culture allows for the determination of specific effects by
particular constituents , it is important that tissue engineering be assessed in vivo.
Commonly, initial evaluations of novel tissue engineered designs are determined by
injections or surgical implantations ofthe tissue engineered components into the
subcutaneous pocket on the dorsal side of athymic mice. 36-38 This enables assessment
of the material biocompatibility without cell source limitations in autologous cell
transplants. In addition to tissue evaluation of subcutaneous growth, cartilage defects
have been filled with polymer and cells, using various polymer tyes in multiple large
animal models , such as horse, sheep, and rabbit. 4o Moreover, investigators have
evaluated both in vitro and in vivo production of engineered cartilage, as constructs
grown in vitro have been transplanted in vivo for further incubation.
Growth Factor Delivery and Cartlage Repair
P LG Microspheres
Another strategy for cartilage repair is to deliver proteins that can control cartilage
or chondrocyte behavior. As PLG has proven biocompatibility and ease of manipulation
of polymer scaffold characteristics 23 it has been actively studied for potential cartilage
tissue repair for over 2 decades. Recently, PLG has also been researched for utilzation
in drug delivery since the small , spherical nature of these polymers enables the
encapsulation of growth factors or other drugs with subsequent controlled delivery to a
specific and designated area.41-45
As a drug delivery vehicle, PLG has most often taken the form of a microsphere.
The feasibility of drug delivery has been demonstrated with numerous growth factors
including IGF- , nerve growth factor (NGF), vascular endothelial growth factor (VEGF),
TGF- , and growth hormone (GH)?5 41,42 46 Many of these studies have been
demonstrated in vitro , but delivery of GH from PLG microspheres has also been shown
in vivo. Controlled delivery of GH in vivo has been shown to elicit systemic effects of
increased growth factor in circulation as well as the upregulation of other factors such as
insulin-like growth factor binding protein-3 (IGFBP-3) or IGF- ,43
Methods and patterns of controlled release have also been determined in vitro.
PLG micro spheres display a tyical release pattern of initial bulk release followed by
controlled release over an extended time period. 46-48 Diffusion of growth factor
tethered to the surface of the microsphere accounts for the initial bulk release from PLG
micro spheres, while degradation of the polymer accounts for release of protein over a
prolonged duration. Degradation of poly (a-hydroxy) acid polymers , such as PLG
occurs initially by hydrolytic cleavage of ester bonds. Once the initial hydrolytic events
have begun, an autocatalytic breakdown of the polymer ensues
, which is referred to as
bulk hydrolysis. Thus , as the polymer degrades , increasing molecules of growth factor
are released to the outside environment.
PLG degradation is known to cause potential harm to growing tissue.22 Consequently,
the affects of both polymer and microsphere composition must be assessed to determe
whether this scaffold supports cartilage tissue regeneration
, and evaluation of such can be
determined by various tissue parameters including matrix accumulation
, cell proliferation
and overall tissue expansion. It is know that factors such as composition and geometry
can affect the degradation rate of the microspheres 23 and further that polymer
degradation rate affects the composition of tissue engineered cartilage 22 possibly by
mechanisms involving regulation of pH. 50 Therefore
, since micro spheres degrade
through bulk hydrolysis of the polymer chains 49 factors that alter microsphere
degradation patterns would also be expected to affect the generation of tissue engineered
cartilage. Examples of such factors include polymer molecular weight and end group
chemistry. Microspheres fabricated with higher molecular weight PLG have been shown
to degrade more slowly than those comprised of lower molecular weight PLG. 
addition, micro spheres with carboxylic acid end groups (uncapped) exhibited increased
degradation rates when compared to those comprised of PLG with ester linkages (capped)
23 Due to the hydrophobic nature of the capped microspheres
, water is not readily taken
into the system, thereby increasing the amount of time it takes for the polymer to
degrade. Degradation rate can also be controlled through neutralizing the acidic
degradation products released by the microspheres , as the encapsulation of salts and
buffers has proven to neutralize the acidic environment around microspheres.23 Thus , the
inuence ofthese parameters on polymer degradation and the surounding environment
suggests that these factors may also infuence the growth of tissue engineered cartilage.
The feasibility of chondrocyte attachment to small synthetic beads and the use of
PLG micro spheres in cartilage tissue engineering designs have both been demonstrated
independently. Microcarrier beads, which were originally used to expand anchorage-
dependent cells in a suspension cell cultue 5! support chondrocyte attachment and
maintain the chondrocyte phenotye. 52 In addition, PLG microspheres , as a sintered
microsphere network, has provided a scaffold for osteoblast attachment and proliferation
for use in bone repair. 54 More recently, PLG micro spheres have been combined in 
cartilage tissue engineering design as controlled delivery vehicles for IGF-I or TGF- .z5
Although these methods describe the culture and attachment of cells to microcarrier
beads and microsphere networks or delivery of micro spheres for use in cartilage tissue
engineering, the use of PLG micro spheres in tissue engineering has not been extensively
studied and prior studies have not demonstrated delivery of chondrocytes solely via
micro spheres and the use of individual micro spheres as a polymer scaffold for cartilage
tissue engineering.
IGF-I Delivery
In tissue engineering, growth factors play an important role in stimulation of
cartilage repair. Various growth factors including IGF-I has been have been shown to be
active in cartilage tissue. IGF-I is a 7.6 kDa protein that signals through the IGF-
receptor on the chondrocyte membrane. Although this factor has an involvement in
maintenance of cartilage homeostasis 56 it is highly regulated by the IGFBP family of
proteins. IGFBPs have been shown to both inibit and facilitate IGF-I stimulation. 57
In cartilage, IGF-I has direct effects on chondrocyte metabolism. In monolayer
chondrocyte culture, cartilage explant culture, or three-dimensional seeding of
chondrocytes onto polymer scaffolds, IGF-I upregulates proteoglycan synthesis and
2455 56 58-61 
. . 
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both the mRA and protein level. 24 60 Both collagen and proteoglycan stimulation of
IGF-I are thought to be dose dependent, and tyical doses used for matrix induction fall
between 10 ng/ml and 300 ng/ml.32 61 Interestingly, however, conficting reports have
indicated differing effects ofIGF-I on cell proliferation. Although IGF-I is generally
considered to stimulation cell proliferation 68 some tissue engineering studies have
reported that IGF-I does not increase DNA content or cell number.
IGF-I effects on matrix stimulation have also been coupled to protection against
matrix breakdown. Under normal culture coriditions with catabolic stimulators such as
interleukin- l (IL- l) or tumor necrosis factor (TN), proteoglycan and collagen synthesis
is suppressed and degradation of proteoglycans is evident. 63-66 However, when cartilage
explants are cultue with IGF- , proteoglycans are synthesized and the presence ofIL- l or
TN does not induce catabolic breakdown of the tissue. 58 Thus , given the pivotal role of
IGF-I in matrix synthesis and prevention of catabolic breakdown, IGF-I has been widely
explored for use in cartilage tissue regeneration.
In tissue engineering applications , supplementation with IGF-I has demonstrated
pronounced effects in vitr0 67 and in vivo. 68 Delivery of growth factors to the
developing cartilage tissue has been demonstrated through a variety of methods. In vitro
growth factors are commonly added exogenously, yet these methods are cumbersome and
protein must be added frequently?4 In vivo however, exogenous delivery of growth
factor presents difficulties , and as a result, development of alternative growth factor
release methods is actively being explored. For example, transfection of chondrocytes
with expression vectors encoding growth factor genes has exhibited promising results as
an alternative method for growth factor delivery. Using this system, transfected
chondrocytes have been seeded in polymer scaffolds or transplanted onto cartilage
disks. Similarly, delivery of growth factor by controlled release from a polymer
scaffold has also been investigated. Gel polymers such as fibrin or alginate can release
free protein 72 or encapsulate a delivery vehicle such as growth factor bound heparin-
sepharose beads; 73 both methods demonstrated sustained release over an extended period
of time.
Biodegradable polymers, such as PLG, have been used for controlled release, and
the feasibility of delivering IGF-I via PLG microspheres has been documented?5
Importantly, IGF-I can be stably loaded into PLG microspheres; under in vitro
conditions , micro spheres incubated in media exhibited IGF-I detection out to 2 weeks.
PLG microspheres loaded with IGF-I have also been used for controlled drug delivery in
vivo. Rats and mice injected with a bolus dosage ofIGF-I demonstrated increases in
IGF-I serum levels over 2 weeks. Recently, PLG micro spheres were used as a growth
factor delivery vehicle in tissue engineering. PLG micro spheres with encapsulated IGF-
or TGF- were included with chondrocytes in photopolymerizing gels. The effects of
growth factor release in this system demonstrated increases in tissue and matrix
production out to 2 weeks.
Thus, the combined promise of controlled delivery with the potential tissue
engineering applications of PLG micro spheres suggest that micro spheres could be used
as a simultaneous repair scaffold and growth factor delivery vehicle. Furher, we predict
that this method ofIGF-I delivery from its concomitant scaffold wil stimulate and
sustain cartilage formation as evaluated by overall tissue production, matrix
accumulation, and cell proliferation.
Hypothesis and Aims
Based on previous studies documenting cell and growth factor delivery using
PLG microspheres , it was the focus of this work to determe their application to
cartilage tissue engineering. Therefore, we hypothesize that the presence of PLG
micro spheres wil enhance cartilage tissue formation and that the process of
chondrogenesis will be affected by variations in physical and chemical properties of the
microspheres. In addition, we predict that IGF-I delivered by controlled release wil
enhance chondrogenesis.
The work presented in this thesis describes two major aims investigated both in
vivo and in vitro. The first aim of this work was to demonstrate that polymer and
microsphere properties would affect cartilage tissue formation. The comparison of in
vivo (chapter 2) and in vitro (chapter 3) studies allows for an evaluation of the
contribution of the material-host interaction and systemic clearance of implant materials
on the processes observed. Specifically, changes in polymer and microsphere
parameters, such as factors that would affect degradation rate or surface area, could be
made so as to enhance tissue and matrix production as well as cell proliferation. The
interactions of cells and polymer/microsphere were evaluated both in vivo and in vitro.
The second aim of this research was to demonstrate that manipulation of the
microsphere through addition ofIGF-I would affect cartilage tissue formation. The
inclusion of both in vivo (chapter 4) and in vitro (chapter 5) models provides for an
understanding of material biocompatibility and physiological transport processes that
affect cartilage tissue engineering. Specifically, the controlled release oflGF-I protein
from the microsphere would act on the chondrocytes to enhance the engineered tissue.
The interactions ofIGF-I as released over a sustained delivery period was evaluated both
in vivo and in vitro.
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Figure 1. Aricular Cartilage is located in the synovial joint (A), organized into a
stratified tissue (B). Cartilage is composed mainly of collagen tye nand aggrecan
which together with other matrix molecules give rise to the mechanical stability of
cartilage tissue (C).
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Figure 2. The structure of poly glycolic acid (A) and polylactic acid (B) differ by a single
methyl group, which lends a hydrophobic characteristic to polylactic acid. PLG
microspheres in this study were fabricated using a random co-polymer of polyglycolic
acid residues (m) and polylactic acid residues (n), where the polymer chain was 50%
polyglycolic acid and 50% polylactic acid.
".-."
lf1
CHAPTER II
A NOVEL INJECTABLE APPROACH FOR CARTILAGE FORMTION
IN VIO USING PLG MICROSPHERES
Summary
This study documents the use of biodegradable poly(lactide-co-glycolide) (PLG)
micro spheres as a novel, injectable scaffold for cartilage tissue engineering in vivo.
Furher, we demonstrate that the presence of polymer enhances tissue growth and
polymer properties have distinct affects on tissue formation. Chondrocytes were
delivered via injection to the subcutaneous space of athymic mice in the presence and
absence ofPLG microspheres. Tissue formation was evaluated up to 8 weeks post-
injection. Progressive cartilage formation was observed in samples containing
microspheres. The presence of micro spheres increased the quantity of tissue formed, the
amount of glycosamioglycan that accumulated and the uniformity of tye II collagen
deposition. Microsphere composition infuenced the growth of the tissue engineered
cartilage. Microspheres with 50 kDa PLG resulted in a larger mass of cartilage formed
and a higher content of proteoglycans. Microspheres comprised of PLG with methyl
f"1
ester caps yielded increased tissue mass and matrix accumulation, but did not display
homogenous matrix deposition. The microencapsulation of Mg(OH)2 had negative
effects on tissue mass and matrix accumulation. Matrix accumulation, cell number and
tissue mass were unchanged by microsphere size, but larger micro spheres increased the
frequency of central necrosis in implants. Overall, we show that cartilage formed with 50
kDa PLG micro spheres generated the most native-like cartilage tissue in this system and
that the data reflect the promising utility of an injectable PLG-chondrocyte system for
tissue engineering applications with applications for controlling tissue growth through
changes in polymer properties.
Introduction
Polylactic acid (PLA), polyglycolic acid (PGA), or their copolymers (PLG) are
commonly used in cartilage tissue engineering. Often these polymers are constructed as
fibers20 or sponges 21 which can be seeded with cells and implanted into the recipient.
One drawback to these scaffolds , however, is the invasive procedure of implantation:
these fibers and sponges must be surgically implanted into the recipient. Poly(lactide co-
glycolide) (PLG) micro spheres offer a non-invasive alternative to the aforementioned
polymer designs.
PLG micro spheres made of varying polymer tyes
75 have predominately been used
as controlled drug delivery vehicles, and their biocompatibility and injectability are
appealing for cartilage tissue engineering applications. Furthermore, the small, spherical
nature ofthese polymers enables the encapsulation of growth factors or other drugs and
their subsequent delivery to a specific and designated area.
The feasibility of chondrocyte attachment to small synthetic beads and the use of
PLG micro spheres in cartilage tissue engineering designs have both been demonstrated
independently. Microcarrier beads , which were originally used to expand anchorage-
dependent cells in a suspension cell culture S! have been demonstrated as a cell carrier
system. Cells have been shown to attach to micro carrier beads made of dextran, collagen
tye I coated dextran, or highly cross-lined collagen tye I and that culture on these
micro carrers maintains the chondrocyte phenotye. 52 More recently, PLG micro spheres
have been used in a cartilage tissue engineering design as controlled release delivery
vehicles for IGF-I or TGF-f3.25 Although these methods describe the culture of
chondrocytes on microbead carriers or delivery of micro spheres in the use of cartilage
tissue engineering, neither has demonstrated delivery of chondrocytes solely via
microcarrier/microsphere for cartilage tissue engineering.
Fibrin glue or hydrogels such as agarose or alginate have also been used for cartilage
tissue engineering. 27 While these are attractive scaffolds for their injectability, they do
not possess the encapsulation capabilities that PLG micro spheres offer. As such, growth
factor delivery to the cartilage tissue construct must be added exogenously to the
scaffold-cell construct.3! Further, these scaffolds do not have properties that readily
enable changes in the degradation rate, whereas PLG polymer chains can be manipulated
to change the scaffold properties.
Factors such as composition and geometry are known to affect the degradation rate of
the microspheres?3 Polymer degradation rate is known to affect the composition of
tissue engineered cartilage 22 possibly by mechanisms involving regulation ofpH.
Since microspheres degrade through bulk hydrolysis of the polymer chains 49 factors that
alter microsphere degradation patterns would also be expected to affect the generation of
tissue engineered cartilage. These factors include polymer molecular weight and end
group chemistry. For instance , micro spheres made from higher molecular weight PLG
degrade more slowly than those comprised of lower molecular weight PLG. Yet another
example is the increased degradation rate for micro spheres with carboxylic acid end
groups (uncapped) compared to those comprised ofPLG with ester linages (capped) .
Due to the hydrophobic nature of the capped micro spheres, water is not readily taken into
the system, thereby increasing the amount of time it takes for the polymer to degrade.
Degradation rate can also be controlled through neutralizing the acidic degradation
products released by the microspheres. The encapsulation of salts and buffers has proven
to neutralize the acidic environment around microspheres
The inuence of these parameters on polymer degradation and the surrounding
environment suggests that these factors may also inuence the growth of tissue
engineered cartilage. The goal of this study was to examie the feasibility of using PLG
microspheres as a delivery vehicle for chondrocytes. Using techniques to determine
GAG production, tissue mass, collagen tye, and tissue morphology the effects of
microsphere size, buffer encapsulation, polymer molecular weight, and polymer end
group chemistry on the production of tissue engineered cartilage was assessed.
Materials and Methods
Cell Culture
Chondrocytes were isolated from the articular cartilage of calf gleno-humeral joints
of2- 10 day old calves (Research 87 , Hopkinton, MA) using 0.3% tye II collagenase
(Worthington), as previously described. After 16 hr of collagenase treatment at 37
isolated chondrocytes were fitered through a 180 f.m fiter to remove any undigested
cartilage particles, washed several times with PBS , and cells were resuspended in Ham
F12 media supplemented with 1% ascorbic acid and 10% FBS.
Microsphere preparation
PLG was obtained form Alkermes, Inc. PLG microspheres were fabricated using the
ProLease process , as described.23 Briefly, 50:50 lactide:glycolide polymer was
dissolved in methylene chloride and atomized over a bed of liquid nitrogen layered on top
of frozen ethanol. The temperature of the system was then maintained at - C to allow
for nitrogen evaporation and removal of methylene chloride into the ethanol phase
(microsphere curing). The resulting microspheres were fitered and then lyophilzed to
remove residual ethanol, and fmally sieved to obtain the desired range of particle sizes.
PLG micro spheres were prepared in groups with average diameter ranging from 63- 199
f.m. Microspheres were also formed using polymers with varying molecular weight and
capped end groups chemistries (Table 1). Separate batches of micro spheres were
prepared with Mg(OH)2 salt. The salt was homogenized in the solution of polymer and
methylene chloride , and the suspension was processed as described above.
Culture Conditions and Implantation
Chondrocytes, at a density of 80 x 10 cells/mL, were mixed with equal volume of
PLG microspheres, at a concentration of 64 mg/mL. The microsphere-chondrocyte
suspension was incubated for 4 hr at 37 C in a shaker incubator to allow for chondrocyte
attachment to the microspheres.
Chondrocyte, microsphere , and chondrocyte-microsphere suspensions were injected
into the subcutaneous space ofthe dorsum of nude mice using an 18-gauge needle. Each
injection contained 20 x 10 cells and/or 16 mg of micro spheres in 500 ilL ofF12 media
(n=3-6 per group tested).
Sample Analysis
All animal procedures were performed under the guidelines of the Institutional
Animal Care and Use Commttee of the University of Massachusetts Medical School.
Mice were sacrificed at 1 , 2 , 4 , 6 , and 8 weeks by anesthesia overdose and samples were
harvested from cell alone and chondrocyte-microsphere samples. No tissue samples
could be harvested from microsphere alone injections, as there was no tissue formation at
the site of injection.
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Upon harvest, the fibrous capsule was removed from each sample. The sample was
weighed and cut in half. Half of the sample was digested with 0. 14 mg papain (Sigma
Chemical Co., St. Louis , MO) for 16 hr at 60 C. Papain digested samples were subjected
to biochemical analysis for cell number and proteoglycan content. The other half of the
sample was fixed in 10% formalin buffer. The fixed sample was embedded in paraffm
and sectioned. Sections were stained with safranin-O. Unstained sections were probed
for collagen tye I and tye n by immunohistochemistry as described below.
Immunohistochemistr
Detection of collagen tyes I and n was achieved by immunohistochemical staining
as described by Madry et al. 70 Briefly, unstained paraffm sections were deparaffinized
rehydrated and washed in PBS with 0. 1 % BSA. Samples were incubated with 0.
hydrogen peroxide , washed, and subjected to digestion for 30 min with 33U/mL bovine
testicular hyaluronidase (Sigma Chemical Co. , St. Louis, MO). Sections were incubated
with a 1 :50 dilution of anti-collagen tye I (Santa Cru Biotechnology, Inc, Santa Cru
CA) for 48 hr at 4 C or a 1:10 dilution of anti-collagen type IT (Chemicon, Temecula
CA) for 2 hr at room temperature , washed, and incubated with a 1 :200 dilution of anti-
IgG biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) for 30 min
at room temperature. Sections were washed and subjected to avidin-biotin-peroxidase
reagent (Vector Laboratories , Burlingame, CA), washed, and exposed to
diaminobenzidine (Vector Laboratories , Burlingame , CA) for 2 min. Sections were
counterstained with 1 % alcian blue for 3 min for collagen tye I staining or 0.02% fast
green for 4 mi for collagen tye IT staining. Digital photomicrographs were obtained
using a Nikon TE 200 microscope equipped with a Spot Junior camera (both from Micro
Video Instruments , Avon, MA).
DNA Quantifcation
Papain digested samples were added to an equal volume of phenol-chloroform-
isoamyl alcohol (Sigma Chemical Co. , St. Louis , MO). Sample tubes were inverted
several times and then centrifuged in a tabletop microcentrifuge at 12 000 x g for 5 min.
The aqueous supernatant was removed from the protein fraction to a clean tube and 1 mL
of cold 100% ethanol was added to the aqueous layer. Samples were stored at -
overnight to precipitate DNA. DNA was pelleted by centrifugation at 12 000 x g for 30
, and upon removal of ethanol, DNA was dried overnight and resuspended in dH
DNA content was read by spectrophotometry at 260 nm and the purity was determined by
the 260/280 ratio.
Proteoglycan Content Analysis
Papain digested samples were analyzed for glycosaminoglycan (GAG) content using the
DMM-dye binding assay.77 Briefly, 50 j.L of papain digested sample was incubated
with 2 mL ofDMM-dye and the reaction was observed on a spectrophotometer at 525
, with shark chondroitin sulfate (Sigma Chemical Co. , St. Louis , MO) used as a
standard.
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Statistical Analysis
All statistics were performed using Sigma StatTM Statistical Softare Version 2.0. To
detect statistical differences between tissue mass, proteoglycan accumulation or DNA
content, two-way ANOV A tests were performed with post-hoc Bonferroni test.
Results
At all time points, samples were recovered from sites that were injected with cells
alone or cells and microspheres. No samples were recovered from sites where
microspheres alone were injected. Histological analyses of the retrieved cartilage
samples demonstrated the presence of micro spheres interspersed with newly forming
cartilage after 1 week (Figure 3A). Chondrocytes remained rounded and those adjacent
to the micro spheres appeared to be attached to the polymer (Figure 3A). After 2 weeks
post-injection, microsphere degradation was evident and newly synthesized matrix was
deposited in the region of the polymer (Figure 3B). Cell attachment to microspheres was
also stil apparent. After 4 weeks, some fragments of PLG micro spheres remained and
there was some evidence of cell attachment to the remaining material (Figure 3C).
Extracellular matrix was uniformly deposited across the entire specimen including into
areas formerly occupied by microspheres. In contrast, cartilage generated from cells
alone contained fibrous tissue interspersed between cartilage regions (Figure 3D).
Moreover, the cartilaginous regions of the cell-only tissue were hypercellular in
comparison with cartilage from cells and polymer, which exhibited lower cell density and
larger distances between cells.
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Given that the presence ofPLG micro spheres appeared to enhance cartilage
formation, subsequent studies focused on the effects of microsphere composition on the
growth of tissue engineered cartilage. Parameters studied included molecular weight
polymer end group, microsphere contents, and microsphere size.
Histological analysis of these samples showed that after two weeks matrix had been
formed in all samples (Figure 4). However, there were distinct trends in matrix
deposition between the different samples. Cartilage grown from cells alone exhibited
many areas of fibrous looking tissue and areas with an intense number of cells (Figure
4C). In all cases, cartilage matrix was not deposited in the area of the injection site until
the microspheres began to degrade. Specifically, in samples harvested from fast
degrading, uncapped, low molecular weight microspheres , matrix deposition appeared to
be unform as early as two weeks (Figure 4A), whereas in slower degrading microsphere
samples , such those containing high molecular weight or capped microspheres , the
proteoglycan matrix was interrpted by undegraded microspheres that left empty gaps of
staining (Figure 4B E). At later time points uniform deposition was observed in fast
degrading microsphere samples (Figure 4D), and as the slower degrading micro spheres
began bioeroding, matrix accumulated in the injection site area (Figure 4F). After 8
weeks, matrix remained distinct from microsphere areas in cartilage formed using capped
micro spheres (Figure 4E).
Tissue mass steadily increased over 8 weeks of culture in samples formed from 50
kDa micro spheres and capped micro spheres (Figure 5A). Growth from 10 kDa
uncapped micro spheres increased slightly until 6 weeks, but more than doubled after 8
weeks of culture. In contrast, samples formed with buffered microspheres initially
exhibited high tissue mass , but as early as 6 weeks drastically decreased in mass. Tissue
mass of samples formed chondrocytes cartilage alone remained unchanged up to 6 weeks
after which there was a sharp increase in tissue mass.
Upon harvest of samples after two weeks, cell number is slightly increased from the
initial 20 x 10 cell seeding density (Figure 5B). However, in all samples seeded with
micro spheres , there was a steady decline in cell number until 6 weeks , when cell density
reached steady state at half of the initial seeding density. Cell number did not vary with
polymer composition or in samples without microspheres. Cell number dropped more
quickly in samples with chondrocytes alone, decreasing to less than half the initial
number at 4 weeks.
GAG content remained steady in samples made from low molecular weight
uncapped, and unbuffered microspheres , while samples made from capped microspheres
high molecular weight micro spheres or cells alone showed increased GAG content over 8
weeks of culture (Figure 5C). In contrast, cartilage formed with buffered micro spheres
exhibited decreased matrix content after 6 weeks. Moreover, cartilage grown using 50
kDa micro spheres had significantly higher proteoglycan content than buffered
micro spheres after 8 weeks (p 02). As well trends showed that cartilage tissue grown
using 50 kDa micro spheres had higher proteoglycan content than cartilage formed using
10 kDa, capped, or cells alone.
Tissue engineered cartilage samples were immunostained for tye I and tye n
collagen (Figure 6). Cartilage grown with micro spheres and chondrocytes exhibited
positive staining for type IT collagen (Figure 6D) and negative staining for type I collagen
(Figure 6C). In contrast, however, cartilage formed from chondrocytes alone exhibited
many pockets of fibrous looking tissue that stained positive for collagen tye I expression
(Figure 6A).
Samples formed from different sized micro spheres exhibited similar matrix
deposition patterns over 8 weeks of culture (Figure 7). After two weeks (Figure 7 A
matrix was not apparent on micro spheres of any size, while after 8 weeks, the
degradation of all micro spheres encouraged matrix deposition across the tissue specimen
including microsphere regions (Figure 7C D). However, after two weeks tissue areas
surrounding the larger micro spheres stained less intensely for proteoglycans (Figure 7B).
Microsphere size did not appear to affect mass of generated tissue. Use 
micro spheres ranging in size from 59 Ilm to 199 Ilm resulting in a steady increased in
tissue mass over 8 weeks post-injection, but there were no significant differences at any
time point (Figure 8A). However, these studies fuher emphasize the difference in tissue
generation following injection of the microsphere-chondrocyte system compared to
admiistration of chondrocytes alone, where mass remained relatively unchanged over 8
weeks.
Furthermore, microsphere size affected total cell number (Figure 8B). Cell number
was doubled from the initial seeding density after 8 weeks in samples formed from 199
f.m 121 f.m, or 93 f.m, which were significantly increased in cell number when
compared to the 59 f.m polymer or cartilage formed from cells alone (p-:0.02). Cell
number was lowest in samples from cells alone.
Microsphere size appeared to have no inuence on proteoglycan content.
Proteoglycan accumulation steadily increased in all cartilage samples after 8 weeks in
vivo (Figure 8C). However, the only statistical differences in GAG content occurred at 6
weeks with 199 f.m samples producing significantly higher GAG content than cells alone
or 59 f.m samples.
Some samples formed from larger micro spheres exhibited a necrotic cavity when
harvested. When these samples were cross sectioned and stained with safranin-O the
iner cavity was hollow (Figue 9A B). The percentage of samples exhibiting central
necrosis increased with microsphere size (Figure 9).
Discussion
This study demonstrates the feasibility of using micro spheres as a novel injectable
cell delivery system for cartilage tissue engineerig. The majority of literature on PLG
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However, recent studies have used micro spheres in tissue engineering in combination
with scaffolds such as PLG or PEO. We demonstrate herein that chondrocytes attach
to PLG micro spheres and form cartilage tissue. This tye of application has broad
ranging possibilties for filling skeletal defects, site specific enhancements , and non-
invasive tissue engineering procedures.
In this study, we demonstrate that injectable chondrocyte delivery using PLG
micro spheres produced cartilage tissue that is more similar to native cartilage than that
grown from cells alone, both in uniformty of tissue, matrix formation, and in cell-cell
spacmg. Matrix deposition remained distinct from the microspheres prior to polymer
biodegradation. Moreover, there was an associated hypercellularity before degradation of
the microspheres; cells appeared packed in non-microsphere regions at the early time
points. As biodegradation began, cells appeared to migrate into the spaces left by
degrading micro spheres and matrix was deposited on top of and in the regions of the
degrading microspheres. At these later time points, cartilage formed from cells alone
continued to exhibit these areas of hyper cellularity. Further, many of these hypercellular
areas were separated by fibrous tissue, which was comprised primarily of tye I collagen.
Matrix deposition patterns in conjunction with the degradation patterns ofthe polymer
suggest that the micro spheres act as a tissue bulking agent; the polymer saves spaces for
the formation of new tissue and the deposition of newly synthesized matrix.
This was further evidenced by the tissue mass data. The mass of material recovered
from the site of administration continued to increase up to 8 weeks post-inection. As the
8 weeks progressed, the polymer continued to degrade and newly formed chondrocyte
tissue accumulated, accounting for the increase in mass. It was also evident that faster
degrading micro spheres resulted in a lower mass recovered 8 weeks post-injection. It is
hypothesized that the higher tissue mass in the 50 kDa samples was likely a product of
effective spacing for a longer time, thereby providing more areas for tissue accumulation.
These observations are consistent with theoretical models of cartilage tissue formation
that predict similar effects on tissue composition due to changes in scaffold degradation
rate.
Since degradation time was also increased by capping the polymer 23 substituting a
methyl ester cap for the free carboxylic end group would seemingly increase the bulking
effect of the tissue. Although we saw a gradual increase in tissue mass after 8 weeks,
these tissue samples only exhibited a moderate increase in GAG content. Moreover
histological analysis showed that the distribution of matrix in capped polymer samples
remained distinct from microsphere regions up to 8 weeks. It has been suggested that
polymers with increased hydrophobicity, such as polylactic acid,19 do not promote cell
attachment or proliferation as well as hydrophilc polymers. Thus , although the
micro spheres provide a moderate bulk effect to the growing tissue, a lack of cell adhesion
to the hydrophobic , capped micro spheres may explain the continued presence 
micro spheres and small amount of matrix deposition onto micro spheres after 8 weeks.
The rate of degradation and its effects on tissue synthesis are related to the rate of
release of acidic degradation fragments. Degradation in poly (a-hydroxy) acid polymers
occurs initially by hydrolytic cleavage of ester bonds. Once the initial hydrolytic events
have begun, an autocatalytic breakdown of the polymer ensues, which is referred to as
bulk hydrolysis. During the phase of bulk hydrolysis, the local pH of the polymer
environment may drop due to the inability of these acidic end fragments to diffse
efficiently. Drops in local pH have been demonstrated to inibit cartilage matrix
assembly.80 Other studies have noted that maintaining a stable pH leads to increased
matrIx pro uctlOn.
In an attempt to buffer these acid fragments, Mg(OH)2 salt was encapsulated in the
micro spheres. This method has been shown to maintain local pH23 around degrading
micro spheres and would be expected to provide a more favorable environment that would
promote cell proliferation and increase matrix production. Contrary to expectations, the
cartilage formed with buffered micro spheres yielded less tissue with lower mass and
GAG content as early as 6 weeks , although cell number was not different from other
microsphere samples. It is possible that excessive Mg(OH)2 release may have increased
the local pH, which has been show to have negative effects on cell metabolism. 50 '
Changing microsphere size impacts the microsphere surface-to-volume ratio and
available area for cell attachment. Histological analysis of safranin-O stained sections
indicated less staining around larger microspheres, suggesting local effects of increased
degradation fragments. Although samples with increased microsphere size exhibited
higher cell number, no corresponding increase in tissue mass or proteoglycan
accumulation was observed. One possible rationale for this observation could be the
higher number of samples made from larger micro spheres exhibiting central necrosis.
The issue of central necrosis is thought to be a limiting factor in the generation of
large volumes of engineered tissues. This phenomenon is thought to be related to a lack
of transport of oxygen to central regions of the growing tissue.8! The fmdings (figure 9)
from the current study indicated that the composition of the polymer scaffold also
regulates the process of central necrosis. Low molecular weight micro spheres, which
generate acidic degradation fragments at a faster rate, and larger microspheres, which
potentially localize greater numbers of degradation fragments , both were seen to be
associated with higher rates of central necrosis. It is important to note that the size of all
samples were similar, such that diffsion distaces , and thus oxygen transport, were
similar in all samples. Together, this suggests that, in this system, clearance of
degradation fragments , and not oxygen transport, appears to be the primary factor
regulating central necrosis.
Overall, samples formed using cells and micro spheres exhibited between 14-36 Jlg of
GAG per mg tissue and 0. 1.9 /lg DNA per mg tissue after 8 weeks , which is similar to
values found for engineered cartilage tissue 37 However, cartilage formed from high
molecular weight micro spheres produced the optimal tissue in this study (Table 2).
These samples produce the highest amount of GAG and total tissue mass without
exhibiting central necrosis of the sample.
In summary, the results presented herein demonstrate the potential utility of an
injectable PLG microsphere-chondrocyte system for tissue engineering applications. The
effects of polymer chemistry and microsphere size were elucidated; at optimal conditions
rapid formation of native-like cartilage occured compared to delivery of cells alone. It is
anticipated that the same approach wil have potential applications in engineering of other
important tissues tyes.
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Polymer Size (urn Mw (kDa) End Group Deg. Rate (week) Buffer
eOOH 2-4
eOOH 2-4
eOOeH
eOOH
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199 eOOH
Table 1. Microsphere composition variables. Microspheres differed with respect to size
molecular weight, end group, degradation rate, and buffer additions. Microspheres
described as low molecular weight are composed of 10 kDa polymer, while 50 kDa is
considered high molecular weight. Capped micro spheres have polymer chains ending
with COOCH3, while uncapped micro spheres polymer chains end with COOH. A plus
symbol indicates the addition ofMg(OH)2 in the micro spheres (see methods).
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Figure 3. Cartilage matrix replaces degraded microspheres. Chondrocytes and
microspheres (A-C) or chondrocytes alone (D) were incubated for 4 hours and injected
subcutaneously in athymic mice for 1 (A), 2 (B) or 4 weeks (C D). All microsphere
samples used low molecular weight, uncapped microspheres. Intact microspheres are
indicated by S; Degrading micro spheres are indicated by D; yellow arrowheads indicate
areas of possible dedifferentiation. Note that micro spheres may appear to have a range of
sizes due to a difference in the plane of sectioning. All pictures were magnified at 200x.

Figure 4. Cartilage tissue matrix deposits differently with respect to polymer
composition. Tissue sections were embedded in parrafm and sectioned. Samples were
stained with safrani-O for proteoglycans. A. Fast degrading, uncapped microspheres, 2
weeks; B. Slow degrading, capped microspheres , 2 weeks; C. Cells alone , no
microspheres, 8 weeks; D. Fast degrading, uncapped micro spheres , 8 weeks; E. Slow
degrading, capped microspheres, 8 weeks; F. Slow degrading, uncapped micro spheres , 8
weeks. All pictures were taken at 200x magnification. Black arrowheads indicate areas
of possible dedifferentiation.
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Figure 5. Biochemical analysis of polymer composition on cartilage tissue formation. A.
Tissue mass varies with polymer composition. Samples were harvested, fibrous capsule
was removed, and wet weight of the samples was taken. Samples formed with higher
molecular weight micro spheres exhibited higher tissue mass than other groups , although
these differences were not statistically significant. B. Cell content did not vary between
groups. DNA was extracted from papain digested samples using phenol-chloroform and
DNA content was determined by spectrophotometer readings at 260 nm. C. GAG
content varies with polymer composition. Biochemical samples were digested with
papain and proteoglycan content was determined using the DMM-dye method.
Samples formed using high molecular weight microspheres were higher in GAG content
than other groups, but were only statistically higher in GAG content than buffered
micro spheres after 8 weeks (p':0. 02). n=3 for buffered microsphere samples, n=4 for
capped microsphere and uncapped, 10 kDa microsphere groups, and n=6 for 50 kDa
microsphere samples.

Figure 6. Imunostained sections for collagen tyes. Cartilage tissue made from cells
alone (a c) or cells and micro spheres (b d) was embedded in parrafm and sectioned.
Sections were immunostained as described for collagen tye I (a,b) or collagen tye II
d). Control cartilage (Car) and tendon (Ten) were also immunostained for collagen
tye II (e) and tye I (t). Positive staining for either collagen tye I (black arrowhead) or
collagen tye IT is indicated by brown. Negative staining for collagen tye I is indicated
by blue. A green color indicates negative staining for collagen tye I (red arrowhead).
All pictures were magnified at 100x.
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Figure 7. Cartilage tissue matrix deposition in samples from different sized
microspheres. Tissue sections were stained for safranin- O in 59 m samples (A C) or
199 m samples (B D). Matrix was distinct from micro spheres after two weeks (A B),
but homogenous for proteoglycans after 8 weeks (C D). Microsphere size does not affect
tissue mass. Samples were harvested, fibrous capsule was removed, and samples were
weighed. Black arrowheads indicate areas of light staining around large microspheres.
All pictures are 200x magnification. n=4 for all samples
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Figure 8. Biochemical analysis of the effects of micros ph ere size on cartilage tissue
formation. A. Tissue mass does not vary with microsphere size, but samples formed
from PLG micro spheres are significantly higher than cartilage formed from cells alone
(p-cO.006). B. Cell content is significantly higher in samples formed from larger
micro spheres (93- 199 m) than from 59 m or cells alone (p-CO.02). C. GAG content
does not vary with microsphere size. n=4 for all groups.
100
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Figure 9. Central necrosis increases with microsphere size. A. Bulk frozen fracture
scanning electron micrograph of central cavity. B. Cross section of safranin-O stained
sample exhibiting central necrosis. C. Percentage of samples exhibiting central necrosis.
Necrotic areas are indicated by CN designation. n=4 for all groups.
Variable Tested OVe rail Outcom e
No real increase in tissue
Low Molecular or GAG accumJlation from
We ight, Uncapped 8 weeks
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Increased tissue and GAG
production
Buffe ring
Capping
High Molecular
Weight
Associated Figure
Figure Sa , 5b
Figure 4d , Sa , 5b
Figure Sa , 5b
Figure Sa , 5b
Table 2. . Summary of overall results. Cartilage harvested from the different conditions
suggest that cartilage formed from high molecular weight micro spheres enhance GAG
production and tissue mass , while not exhibiting central necrosis.
CHAPTER III
PLG MICROSPHERES As A MOLDABLE SCAFFOLD FOR
CARTILAGE TISSUE ENGINEERIG166
Summary
This study documents the use of biodegradable poly(lactide-co-glycolide) (PLG)
micro spheres in vitro as a moldable scaffold for cartilage tissue engineering and evaluates
the effects of microsphere composition on tissue growt in vitro. First, distinct
differences were noted between cartilage generated with only cells and that grown with
microspheres and chondrocytes. Specifically, cartilaginous tissue formed using
chondrocytes and micro spheres maintained thickness, shape , and chondrocyte phenotye
as indicated by type II collagen production. The presence of micro spheres further
enhanced total tissue mass and the amount of glycosamioglycan that accumulated.
Second, microsphere properties, such as polymer molecular weight, end group chemistry,
and buffer inclusion, have direct and different affects on tissue growth. Specifically,
higher molecular weight PLG resulted in a larger mass of cartilage-like tissue formed and
a higher content ofproteoglycans. Cartilage-like tissue formed using micro spheres made
from low molecular weight and free carboxylic acid end groups did not display increases
in tissue mass, yet modest increased proteoglycan accumulation was detected.
Microspheres comprised of PLG with methyl ester end groups yielded a steady increase
in tissue mass , with no real increase in matrix accumulation. Samples formed with
microencapsulated Mg(OH)z indicated decreased tissue mass and matrix accumulation.
The results gained from this study were consistent with those results from the in vivo
cartilage regeneration model. Moreover, the data herein reflect the potential utilty of a
moldable PLG-chondrocyte system for tissue engineering applications and demonstrate
that scaffold properties can be changed to control tissue growth.
Introduction
Many different types of polymers have been used for cartilage tissue engineering.
Some of the most common polymers include polylactic acid (PLA), polyglycolic acid
(PGA), or their copolymers (PLG), often in the form offibers2o or sponges.21 These
polymers have been known for their biocompatibilty and can be easily seeded with cells
and implanted into the recipient. PLG has also been used to form microspheres, whose
small, spherical nature enables the encapsulation of buffers, growth factors or other
proteins for controlled release. 42 Although PLG micro spheres have been
predominately used for controlled drug delivery, more recently, they have been
demonstrated for use in tissue engineering for drug delivery5 or as an injectable
scaffold ? Although PLG microspheres and chondrocytes have been delivered in vivo via
direct injection 82 they could potentially be used in vitro as a moldable scaffold. Current
polymers used as moldable scaffolds include fibrin glue or alginate
27 yet these
scaffolds do not possess modulatory structural and chemical properties that could
potentially optimize tissue growth.
In contrast, PLG polymer chains can be manipulated to change the scaffold
properties 82 Engineered tissue growth in vivo was affected when the compositional
make-up ofthe polymer used in the fabrication ofPLG micro spheres was altered.
Changes that alter molecular weight to increase degradation time also increased matrix
accumulation, whereas microspheres loaded with a buffering agent had negative effects
on matrix accrual. Other studies suggest that polymer degradation rate can affect the
composition of engineered cartilaginous tissue
22 possibly by mechanisms involving
regulation of pH. 50 Since microspheres degrade through bulk hydrolysis of the polymer
chains 49 factors that alter microsphere degradation patterns would also be expected to
affect the generation of tissue engineered cartilage.
As such, specific changes in microspheres composition have been demonstrated to
inuence degradation rate including polymer molecular weight, end group chemistry, and
the controlled release of a buffering agent. For instance , micro spheres made from higher
molecular weight PLG degrade more slowly than those comprised of lower molecular
weight PLG. Yet another example is the increased degradation rate for microspheres
with carboxylic acid end groups (uncapped) compared to those comprised ofPLG with
ester linages (capped) .23 Due to the hydrophobic nature of the capped microspheres
water is not readily taken into the system, thereby increasing the amount of time it takes
for the polymer to degrade. Degradation rate can also be controlled through neutralizing
the acidic degradation products released by the micro spheres. The encapsulation of salts
and buffers has proven to reduce the PLG degradation rate, likely due in part to
neutralization of acidic byproducts from microsphere degradation.
In the current investigation, it was desired to expand on these observations and
examie the feasibility of micro sphere-mediated construction of cartilage-like tissue in
vitro. The in vitro environment is more amenable to external controls; biochemical or
mechanical conditions can be easily repeated, as a known amount of growth factor, stress
strain, etc. can be consistently delivered and monitored. Similarly, the effects ofthese
conditions are easier to assess , since the environment is controlled and not coupled to
undefmed endogenous factors. In vitro culture also offers the abilty to mold cells and
polymer simultaneously into a shaped implant.
The inuence of various parameters on polymer degradation and engineered
cartilage-like tissue-like tissue in vivo suggests that these factors may also infuence the
growth of engineered tissue in vitro. The goal ofthis study was to examine the feasibility
of using PLG micro spheres in vitro as a moldable scaffold for cartilage tissue
engineering. Using techniques to determe GAG production, tissue mass, collagen tye
and tissue morphology the effects of buffer encapsulation, polymer molecular weight
and polymer end group chemistry on the production of tissue engineered cartilage-like
tissue were assessed.
Materials and Methods
Cell Culture
Chondrocytes were isolated from the articular cartilage of calf gleno-humeral joints
of2- 10 day old calves (Research 87 , Hopkinton, MA) using 0.3% type II collagenase
(Worthington), as previously described. After 16 hr of collagenase treatment at 37
isolated chondrocytes were fitered through a 180 /lm fiter to remove any undigested
cartilage particles , washed several times with PBS , and cells were resuspended in Ham
F12 media supplemented with 1 % ascorbic acid and 10% FBS.
Microsphere preparation
PLG was obtained form Alkermes, Inc. PLG micro spheres were fabricated using the
ProLease process, as described?3 Briefly, 50:50 lactide:glycolide polymer was
dissolved in methylene chloride and atomized over a bed of liquid nitrogen layered on top
of frozen ethanol. The temperature of the system was then maintained at - C to allow
for nitrogen evaporation and removal of methylene chloride into the ethanol phase
(microsphere curing). The resulting micro spheres were filtered and then lyophilzed to
remove residual ethanol, and fmally sieved to obtain the desired range of particle sizes.
PLG micro spheres were prepared in groups with average diameter ranging from 52-
/lm. Microspheres were also formed using polymers with varying molecular weight and
capped end groups chemistries (Table 3). Separate batches of micro spheres were
prepared with Mg(OH)2 salt. The salt was homogenized in the solution of polymer and
methylene chloride, and the suspension was processed as described above.
Culture Conditions and Implantation
Chondrocytes, at a density of 80 x 10 cells/mL, were mixed with equal volume of
PLG micro spheres, at a concentration of 64 mg/mL. The microsphere-chondrocyte
suspensio was incubated for 4 hr at 37 C in a shaker incubator to allow for chondrocyte
attachment to t e microsp eres.
For in vitro culture, the wells of a 12-well plate were covered with a surface layer of
5% agarose to prevent cell adhesion to the bottom of the well , and a cylinder measuring
1 cm in diameter was placed in the well. Agarose solidification sealed the cylinder to the
well. Chondrocytes along, micro spheres alone, and a mixed system of chondrocytes and
micro spheres were delivered as a 500 !JL volume to the cylinders. 
Each delivery
contained 20 x 10 cells and/or 16 mg of micro spheres in 500 j.L ofF12 media (n=2-
per group tested).
Sample Analysis
Upon harvest, each sample weight was taken, which included the mass ofthe
microspheres, and cut in half. Half of the sample was digested with 0. 14 mg papain
(Sigma Chemical Co. , St. Louis, MO) for 16 hr at 60 C. Papain digested samples were
subjected to biochemical analysis for cell number and proteoglycan content. The other
half of the sample was fixed in 10% formalin buffer. The fixed sample was embedded in
paraffm and sectioned. Sections were stained with safrani-O. Unstained sections were
probed for collagen tye I and tye IT by immunohistochemistry as described below.
Immunohistochemistr
Detection of collagen tyes I and IT was achieved by immunohistochemical staining
as described. 82 Briefly, unstained paraffm sections were incubated with a 1 :50 dilution
of anti-collagen tye I (Santa Cruz Biotechnology, Inc , Santa Cruz, CA) for 48 h at 4
or a 1: 10 dilution of anti-collagen tye n (Chemic on, Temecula, CA) for 2 h at room
temperature, washed, and incubated with a 1:200 dilution ofanti-IgG biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA) for 30 min at room
temperature. Sections were counter stained with 1 % alcian blue for 3 min for collagen
tye I staining or 0.02% fast green for 4 min for collagen type n staining. Digital
photomicrographs were obtained using a Nikon TE 200 microscope equipped with a Spot
Junior camera (both from Micro Video Instruments, Avon, MA).
DNA Quantifcation
DNA quantification was performed as described. Briefly, papain digested samples
mixed with phenol-chloroform-isoamyl alcohol (Sigma Chemical Co. , St. Louis , MO).
DNA was extracted and content was read by spectrophotometry at 260 nm and the purity
was determined by the 260/280 ratio. A known number of chondrocytes was used as a
standard for calculation of cell number.
Proteoglycan Content Analysis
Papain digested samples were analyzed for glycosamioglycan (GAG) content using the
DMM-dye binding assay.77 Briefly, 50 JlL of papain digested sample was incubated
with 2 mL ofDMM-dye and the reaction was observed on a spectrophotometer at 525
, with shark chondroitin sulfate (Sigma Chemical Co. , St. Louis, MO) used as a
standard.
Statistical Analysis
All statistics were performed using Sigma Stat Statistical Software Version 2.0. To
detect statistical differences between tissue mass, proteoglycan accumulation or DNA
content, two-way ANOV A tests were performed with post-hoc Bonferroni test for
pairise comparison.
Results
Samples were harvested from wells containg cells alone or cells and microspheres.
The gross morphology of harvested samples suggested major differences in sample
structure. Tissue specimens harvested from cells alone formed a thin layer oftissue over
the agarose layer and often picked up the coloration of the media (Figure lOA). After 8
weeks, tissue formed from cells alone took a disk-like shape, but the tissue remained
translucent and thi (Figure lOB). In contrast, samples formed from cells and
micro spheres had a defmed disk-like shape at early time points (Figure 10C) that
continued to increase in tissue firmess, thickness and height with incubation time
(Figure 10D).
Microsphere composition also affected the gross morphology ofthe tissue. Samples
formed from micro spheres made from low molecular weight and uncapped polymer, high
molecular weight polymer, or capped polymer formed defmed cartilage-like disks.
However, samples formed from buffered micro spheres formed tissue samples that
appeared less stable when harvested (data not shown).
Samples stained with safranin-O demonstrated differences between tissue formed
from cells alone or from cells and high molecular weight microspheres. Samples formed
from cells alone appeared hypercellular throughout the study, but stained uniformly with
safranin-O (Figure llA, Table 3). In contrast, staining patterns clearly demonstrate the
presence of microspheres , as well as exclusion of matrix deposition from these areas until
the microsphere began to degrade (Figure liB).
Tissue mass steadily increased in samples formed from cells alone or cells and high
molecular weight microspheres over 8 weeks of culture. At each time point samples
formed with cells and microspheres had a 3 to 4-fold increase over tissue formed from
cells alone (p..O.OOl) (Figure 12A).
Initially, GAG content was similar in samples formed from cells and micro spheres
and those formed with cells alone. All samples increased in GAG content throughout the
8 weeks, however, differences were seen as early as 4 weeks. Samples formed using
cells and micro spheres had a 5-fold difference in GAG content after 4 weeks and a 2.
fold difference in GAG content after 8 weeks (Figure 12B).
When cell content was analyzed, a significant decrease was noted in the number of
cells in samples formed from cells alone from 2 to 8 weeks (p..0.004). However, the
total number of cells remained fairly constant in samples formed with cells and
microspheres. Total cell number was 30-50% of the initial cell load in both sample sets
(Figure 12C).
Histological analysis of samples formed from cells and micro spheres fuher revealed
differences between tissues formed using micro spheres of different polymer
compositions. In all samples , micro spheres did not begin to degrade until after 4 weeks
and at the later time points , microsphere remains were stil detectable. As well, safranin-
o staining did not appear in the area ofthe micro spheres until degradation of the polymer
occurred. Staining in samples formed from micro spheres of 50 kDa or 10 kDa, uncapped
polymer appeared uniform across the tissue both at early and late time points (Figure
13A, B , E). At early time points, tissue formed from micro spheres containing buffer
exhibited homogenous staining across the tissue (Figure 13C), yet as early as 6 weeks
these samples exhibited minimal staining for proteoglycans (Figure 13D). Additionally,
the micro spheres in samples formed using buffered microspheres were not easily
observed (Figure 13D). After 6 weeks, matrix deposition in microsphere regions was
apparent in samples formed using micro spheres of high molecular weight polymer
(Figure 13E), while samples formed using micro spheres with capped polymer did not
deposit matrix in the microsphere areas at late time points (Figure 13F).
Tissue mass was assessed in samples formed with different microsphere
compositions. In general, samples increased in tissue mass over the 8 weeks of culture.
At intermediate time points , samples formed from micro spheres with buffer or high
molecular weight polymer had the highest tissue mass, which was significantly higher
than other polymer counterparts (pO:O.04) (Figure 14A). However, samples formed using
buffered micro spheres did not form compact and dense tissue, as was formed with all
other microsphere samples. After 8 weeks samples formed with buffered micro spheres
had signficantly decreased weight from those harvested at 4 or 6 weeks (pO:O.03) (Figure
14A).
Proteoglycan content also varied with polymer composition. Samples formed from
microspheres with low molecular weight, uncapped or capped polymer demonstrated
modest increases in GAG content, while the GAG content in samples formed from
buffered micro spheres remained stagnant throughout the time course (Figure 14B). 
contrast, samples formed with micro spheres of high molecular weight polymer had an
overall increase in GAG content over the time course. After 8 weeks , GAG content had a
fold minimum difference from tissue formed with different microsphere compositions
(p-:0.005) (Figure 14B).
At the fIrst time point of 2 weeks, cell number was decreased in all samples to about
half of the initial cells delivered. These numbers did not vary signficantly throughout
the 8 week time course and no differences were detected between any of the samples
(Figure 14C).
Tissue samples were immunostained for collagen tye I and collagen tye n (Figure
15). All samples stained negative for collagen tye I, as evidenced by the blue
counterstain (Figure 15A, C). In contrast, the homogenous brown coloration indicated
positive staining in all tissue sections for collagen tye n (Figure 15B , D).
Discussion
The majority of literature on PLG microspheres to date describes their use in drug or
growt factor delivery, 42,75 but recent studies examine their potential in tissue
engineering. 82 PLG micro spheres can be fabricated to achieve changes in the
microsphere composition 82 which have been shown to affect cartilage-like tissue
growth in vivo.82 This study indicates that PLG micro spheres can be used as a moldable
scaffold in vitro , which would have use in filling specific cartilage defects or in
applications where complex geometries are needed. In this study, the presence of
polymer served to bulk cartilage-like tissue, allowing it to be shaped into disks that
maintained thickness and shape, while preserving additional space for matrix
accumulation.
Although tissue engineering often involves a polymer scaffold, several studies have
investigated the utility of implants composed of cells alone. Chondrocytes have been
cultured in vitro as pellets16 or in a method known as alginate recovered
chondrocytes 83 as these methods maintain the chondrocyte phenotye of a well
developed collagen and proteoglycan matrix. Although phenotye maintenance and
retention can be argued 17 these culture systems exhibit hypercellularity and a lack of
cell spacing, 19 consistent with the results demonstrated in this study in cartilage-like
tissue from chondrocytes alone. In contrast, chondrocytes in tissue formed with PLG
micro spheres appeared densely packed when micro spheres were stil intact, but as
microspheres began to degrade , the chondrocytes appeared more appropriately spaced
consistent with in vivo observations.82 Similarly, tissue formed from chondrocytes and
micro spheres exhibited a cell density that was more similar to native cartilage tissue than
chondrocytes cultured in the absence of a polymer scaffold (Table 4).
Distinctions between tissue grown with cells and micro spheres or with cells alone
were further evidenced by tissue analyses. Cartilage-like tissue formed using
chondrocytes and micro spheres maintained a significantly higher tissue mass throughout
the 8 weeks of study. In addition, after 4 weeks in culture the matrix accumulation in
samples formed using micro spheres remained greater than cartilage-like tissue formed
from cells alone and exhibited almost 50% of matrix accumulation in native cartilage
tissue (Table 2). Interestingly, although total cell number did not differ between the two
groups, the amount of GAG /DNA suggested that fewer cells were responsible for larger
accumulation of matrix. These differences suggest that PLG micro spheres provide a
scaffold for engineered cartilage-like tissue in vitro that enhances tissue and matrix
growth, and this enhancement could be attributed to limitations in oxygen 
diffsion. The
potential benefits of low oxygen tension have indicated stimulation of chondrocyte
redifferentiation and increases in GAG content.
85 Because the diffusional distance
would be greater in samples formed with microspheres, the oxygen tension in these
samples is likely lower and may promote more optimal growth conditions than methods
involving cell alone delivery.
Given that PLG micro spheres enhance tissue and matrix growth, it is important to
determine whether microsphere composition affects engineered tissue growt in vitro.
Microsphere degradation in vitro is known to be slower than degradation in viv0 . Data
from cartilaginous tissue formed with fast degrading and uncapped polymer indicated
that microsphere degradation was detected as early as 2 weeks. In contrast, cartilage-
like tissue formed in vitro from micro spheres with the same composition displayed no
evidence of degradation before 4 weeks (Figure 13). Similarly, cartilage-like tissue
formed using slower degrading micro spheres exhibited microsphere breakdown by 4
weeks in vivo , while in vitro micro spheres with buffer, capped polymer or high
molecular weight polymer remained intact until the 6 week time point. After 4-6 weeks
in vitro, matrix was deposited on microspheres made from fast degrading, uncapped
polymer or high molecular weight polymer, respectively, but in micro spheres formed
with capped polymer matrix remained excluded and cells were densely packed in the
spaces not occupied by microspheres.
Interestingly, cell number remains largely unchanged in the different samples
suggesting that matrix deposition inside the regions of the micro spheres may be due to
cell migration and resultant changes in cells spacing. Moreover, the hydrophobic cap
may contribute to the lack of cell spacing demonstrated in vitro and in vivo
82 as
polymers with increased hydrophobicity, such as polylactic acid,19 do not promote cell
attachment or proliferation as well as hydrophilic polymers. In addition, a lack of cell
adhesion to the hydrophobic, capped micro spheres may explain the continued presence 
microspheres , small amount of matrix deposition onto micro spheres, and minimal
proteoglycan accumulation after 8 weeks.
We also tested the effects of buffer release to the growing cartilage-like tissue, since
encapsulation of Mg(OH)2 salt has been shown to decrease microsphere degradation
rate . Release of buffer would be expected to provide an environment that might
counteract microsphere bulk hydrolytic breakdown
78 that causes decreases in pH, which
in tur has been shown to mediate matrix integrity.
8o However
, in vitro cartilage-like
tissue formed from buffered micro spheres negatively affected tissue mass and matrix
accumulation, consistent with in vivo data.
82 In this study, the negative effects of the
buffer were noted as early as 6 weeks by evidence of poor sample staining with safrani-
o and drastic decreases in proteoglycan accumulation and cell number, suggesting that
release of buffer might be a contributing factor in the poor tissue growth.
In summary, we report for the first time a PLG microsphere-chondrocyte system
suitable for in vitro production of molded cartilaginous tissue. Characteristics of
cartilage-like tissue produced in vitro were similar to those of tissue produced in vivo
using these microspheres 82 with consistent and specific effects of changes in the polymer
scaffold on developing tissue. The characteristics of the cartilage-like tissue produced by
this in vitro system are native-like and may have utilty for tissue engineering
applications of multiple tissue tyes.
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Polymer Size (urn) Mw (kDa) End Group Deg. Rate (week) Buffer
Fast degrading,
uncapped GOOH 2-4
Buffered GOOH 2-4
Gapped GOOGH
High molecular
weight GOOH
Table 3. Microsphere composition variables. Microspheres differed with respect to size
molecular weight, end group, degradation rate, and buffer additions. Microspheres
described as low molecular weight are composed of 10 kDa polymer, while 50 kDa is
considered high molecular weight. Capped microspheres have polymer chains ending
with COOCH3, while uncapped micro spheres polymer chains end with COOH. A plus
symbol indicates the addition ofMg(OH)2 in the micro spheres (see methods).

Figure 9. Gross morphology of in vitro cartilaginous disks. Cartilage disks were formed
using chondrocytes alone (A , B) or chondrocytes and 50 kDa PLG micro spheres (C , D).
Cloning cylinders , 1 cm in diameter, were used to mold cartilage-like samples. Samples
were harvested at 2 weeks (A, C) and 8 weeks (B , D). The diameter of the disk was 1 cm
in B- , whereas cartilage-like tissue from chondrocytes only at 2 weeks exhibited a 40%
reduction in diameter.

Figure 10. Histological analysis of cartilaginous disks stained with Safranin-O. A.
Cartilage-like tissue formed from chondrocytes alone at 8 weeks. B. Cartilage-like tissue
formed from chondrocytes and PLG micro spheres at 8 weeks. Cartilage formed from
cells alone exhibited hypercellularity and lack of appropriate cell spacing, while cartilage
formed with cells and micro spheres had more appropriate cell spacing after 8 weeks. All
pictures were magnified 100x.
300
200
2200
1100
80E+07
= 120E+07CD .
00E+06
OOE+OO
-- 
Cells
Cells + Microspheres
week 2 week 4 week 8
-- 
Cells
Cells + Microspheres
week 2 week 4 week 8
-- 
Cells
Cells + Microspheres
week 2 week 4 week 8
Figure 11. Biochemical analysis of in vitro cartilaginous tissue growth using PLG
microspheres. A. Cartilage-like tissue formed in the presence ofPLG microspheres
demonstrated higher tissue mass than tissue formed from cells alone. B. Cartilage-like
tissue formed with cells and microspheres exhibited increased GAG content. C. Cell
content did not vary between samples made from cells and micro spheres or from cells
alone. n=4 for all groups.

Figure 12. Histological analysis of matrix deposited in the growing cartilage-like
samples. Tissue sections were cut from paraffin embedded samples and stained with
safranin-O. A. Fast degrading, uncapped micro spheres at 4 weeks; B. Fast degrading,
uncapped micro spheres at 6 weeks; C. Buffered micro spheres at 4 weeks; D. Buffered
micro spheres at 6 weeks; E. High molecular weight microspheres at 6 weeks; D. Capped
micro spheres at 6 weeks. All pictures are magnified 200x. Intact micro spheres and
bioeroding micro spheres are differentiated by (S) and (D), respectively. Black
arrowheads indicate possible areas where microspheres may be present in cartilaginous
tissue formed with buffered microspheres. Note that micro spheres may appear to have a
range of sizes due to a difference in the plane of sectioning.
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Figure 13. Biochemical analysis of polymer composition on in vitro cartilage-like tissue
formation. A. Tissue mass varies with polymer composition. Samples were harvested
fibrous capsule was removed, and wet weight of the samples was taken. Samples formed
with higher molecular weight micro spheres exhibited higher tissue mass than other
groups , although these differences were not statistically significant. B. Cell content did
not vary between groups. DNA was extracted from papain digested samples using
phenol-chloroform and DNA content was determined by spectrophotometer readings at
260nm. C. GAG content varies with polymer composition. Biochemical samples were
digested with papain and proteoglycan content was determined using the DMM-dye
method. Samples formed using high molecular weight microspheres were higher in GAG
content than other groups, but were only statistically higher in GAG content than
buffered micro spheres after 8 weeks (pOOO.02). n=2 for buffered microsphere samples
n=3 for uncapped, 10 kDa micro spheres samples , and n=4 for 50 kDa microsphere or
capped microsphere groups.

Figure 14. Imunostained sections for collagen tyes. Cartilage-like tissue made from
cells alone (A, C) or cells and microspheres (B , D) was embedded in parrafin and
sectioned. Sections were immunostained as described for collagen tye I (A, B) or
collagen tye IT (C , D). All samples exhibited positive staining for collagen tye IT
indicated by brown, and negative staining for collagen tye I, as indicated by blue.
Neither positive staining for collagen tye I or negative staining for collagen type IT was
not observed in any samples.
GAG GAG/DNA DNA/tissue
(%ww (ug/ug) (ug/mg)
Chondocytes only 77% 41.
PLG microspheres -
high molecular weight 23% 114
Cartilage 5. Jb 120
e% ww - as percentage of wet weight
Table 4. Summary of compositions and comparison with native bovine articular
cartilage. Total GAG contents were normalized to either wet weight or DNA content and
compared between cartilage formed from cells alone, cells and 50 kDa PLG
microspheres , and native bovine cartilage tissue. Total DNA was normalized to tissue
wet weight and compared between the groups.
CHAPTER IV
ENHCEMENT OF CHONDROGENESIS THROUGH CONTROLLED
RELEASE OF IGF -I FROM AN INJECTABLE MICRO SPHERE
SCAFFOLD
Summary
PLG micro spheres have been used independently as a drug delivery vehicle or as a
scaffold for cartilage tissue engineering. This study reports the simultaneous use of PLG
micro spheres as scaffold for cartilage regeneration and IGF-I controlled release vehicle
and demonstrates that delivery through controlled release can enhance cartilage tissue
growt. Release profiles for IGF-I doses from 0.0007% and 0.3% were evaluated in vitro
and the effects of these doses on chondrogenesis were evaluated in vivo. Profiles
demonstrated biphasic IGF-I release, with initial bursts ofless than 13% and controlled
release detecting release of 40% of the total IGF-I load at 6 weeks and continued
detection at 8 weeks in all doses tested. Release oflGF-I to growing cartilage tissue
resulted in dose-dependent increases in tissue mass , GAG, and collagen tye II. IGF-
release increased proteoglycan accumulation in a dose-dependent manner at each time
point, with the highest GAG stimulation exhibited at 8 weeks. In contrast, although IGF-
I increased collagen tye IT accumulation at each time point, the stimulation of collagen
production was highest at 2 weeks and decreased with the duration of the study. Overall
the samples receiving 0.3% IGF-I exhibited the most tissue, GAG and collagen tye II
accumulation. Additionally, in samples receiving IGF- , chondrocyte migration into and
matrix deposition onto microspheres was dose-dependently enhanced at 4 weeks, with the
most matrix deposition on micro spheres occurring in samples receiving 0.3% IGF-I. The
0.3% IGF-I group also exhibited the most intense staining for proteoglycans and collagen
tye IT after 8 weeks.
Introduction
The poor regenerative capacity of cartilage tissue and the current limitations of
cartilage repair technologies make tissue engineering a promising repair alternative. 
Tissue engineering strategies tyically involve a polymer, cell source and/or growth
factor, and studies of each ofthese factors have been of great interest for cartilage repair.
As a major component for tissue repair, the scaffold has been an integral area of
study. As such, repair scaffolds have varied from pre-shaped biomaterials such as PLA
PGA or PLG 21 to injectable and moldable materials such as alginate 87 or fibrin?4
Varying success has been demonstrated with many tyes of polymers; however, PLG
micro spheres are an attractive scaffold for cartilage tissue engineering as they have been
demonstrated to support cartilage growth as a solitary injectable scaffold in vivo or a
moldable scaffold in vitro. 166 PLG micro spheres when incubated with chondrocytes
have been shown to develop tissue volume in a constrained or molded system 166 or form
cartilage nodules when injected subcutaneously,82 demonstrating that PLG micro spheres
support chondrogenesis.
Delivery of growth factors has also been shown to enhance cartilage tissue
engineering and delivery has been demonstrated through a variety of methods. Growth
factors are commonly added exogenously in vitro , yet these methods are cumbersome, as
protein must be added frequently.24 Additionally, strategies for exogenous delivery of
growth factor in vivo are not straightforward, and as a result, development of alternative
growth factor release methods is actively being explored. Transfection of chondrocytes
with expression vectors encoding growth factor genes has exhibited promising results as
an alternative method for growth factor delivery. Using this system, transfected
chondrocytes have been seeded in polymer scaffolds or transplanted onto cartilage
disks. Additionally, delivery of growth factor by controlled release from a polymer
scaffold has also been investigated. Gel polymers such as fibrin or alginate can release
free protein 72 or encapsulate a delivery vehicle such as growth factor bound heparin-
sepharose beads/ both methods demonstrated sustained release over an extended period
of time.
Biodegradable polymers such as PLG have also been used for controlled release.
One particularly suitable strategy for controlled delivery from PLG is in the form of
microspheres, which have predominately been used as drug delivery vehicles.
Recently, PLG microspheres have been used as a growth factor delivery vehicle in tissue
engineering. PLG micro spheres with encapsulated insulin-like growth factor-I (IGF-I) or
transforming growth factor- (TGF - ) were incorporated with chondrocytes in
photopolymerizing gels. The effects of growt factor release in this system demonstrated
increases in tissue and matrix production out to 2 weeks?5 Thus , the promise of
controlled delivery combined with the tissue engineering applications of PLG
micro spheres suggest that microspheres could be used as a simultaneous repair scaffold
and growth factor delivery vehicle.
One such growth factor that would be appropriately delivered from PLG
micro spheres for engineered cartilage tissue is IGF-I. IGF-I is an important growth factor
for chondrogenesis, as it has been shown to stimulate matrix synthesis 45 59 and cell
proliferation 6o and protects against matrix catabolism. 59 In tissue engineering
applications, supplementation with IGF-I has demonstrated pronounced effects in
vitr0 67 and in vivo. 68 In addition, drug delivery studies have demonstrated stably
loaded IGF-I into PLG micro spheres for sustained delivery,74 while controlled release in
vivo has demonstrated increases oflGF-I serum levels in rats and mice.
Given that PLG micro spheres can act as a solitary scaffold and have been
demonstrated for use in controlled release, we sought to combine these fuctions to
produce a simultaneous scaffold and growth factor delivery vehicle. We further
hypothesized that release oflGF-I from PLG microspheres would enhance cartilage
matrix assembly in engineered cartilage.
Materials and Methods
Cell Culture
Chondrocytes were isolated from the articular cartilage of calf gleno-humeral joints
of2- 10 day old calves (Research 87 , Hopkinton, MA) using 0.3% type II collagenase
(Worthington), as previously described . After 16 hr of collagenase treatment at 37
isolated chondrocytes were filtered through a 180 Jlm fiter to remove any undigested
cartilage particles , washed several times with PBS , and cells were resuspended in Ham
F12 media supplemented with 1% ascorbic acid.
IGF-I protein preparation
To prepare the protein for microsphere encapsulation, recombinant human IGF-
protein (PeproTech, Inc , Rocky Hil, NJ) was dissolved in 100 mM solution of acetic acid
for a 1 mg/mL solution. The protein solution was then sprayed though a sonic nozzle
over liquid nitrogen, transferred to - C for nitrogen evaporation, and lyophilized.
Microsphere Preparation
PLG was obtained form Alkermes, Inc. PLG microspheres were fabricated using the
ProLease(I process, as described . Briefly, 50:50 lactide:glycolide polymer with a 50
kDa molecular weight and lyophilized IGF-I protein was dissolved in methylene chloride.
This solution was atomized over a bed of liquid nitrogen layered on top of frozen ethanoL
The temperature of the system was then maintained at - C to allow for nitrogen
evaporation and removal of methylene chloride into the ethanol phase (microsphere
curing). The resulting micro spheres (loaded microspheres) were filtered and then
lyophilzed to remove residual ethanol, and fmally sieved to obtain the desired range of
particle sizes. Microspheres ofthe same polymer tye were prepared without IGF-
(unoaded microspheres), as described.
IGF-I load
As prepared, micro spheres had a 1% IGF-I load. To obtain the desired dosage of
IGF-I from 0.0007% to 0. , loaded micro spheres and unloaded microspheres were
mixed at different concentrations (Table 5).
IGF-I Release
Microspheres at varying IGF-I concentrations were incubated in vitro for up to 56
days in Ham s F12 media with 0.3% carboxymethylcellulose (Sigma Chemical Company,
St. Louis, MO). At each time point, media was collected and replaced with fresh media.
(n=3 for each effective IGF-I load).
Media was assayed for IGF-I content using the Human IGF-I Quantikine ELISA
kit according to the manufacturers specifications (R&D Systems , Inc, Minneapolis, MN.
IGF-I standards and collected media were incubated on an ELISA plate pre-coated with
mouse monoclonal IGF-I antibody for 2 hr at 4 C. Unbound samples were washed from
plate and the plate was incubated with an IGF-I polyclonal antibody conjugated to
horseradish peroxidase at 4 C. Excess secondary antibody was washed from the plate
and wells were incubated with hydrogen peroxide/chromogen for detection ofIGF-
Optical densities were read at 450nm.
Culture Conditions and Implantation
Chondrocytes were mixed with equal volume ofPLG micro spheres , and the
microsphere-chondrocyte suspension was incubated for 4 hr at 37 C in a shaker
incubator, as described.
Chondrocyte-microsphere suspensions were injected into the subcutaneous space of
the dorsum of nude mice using an 18-gauge needle. Each injection contained 20 x 10
cells and/or 16 mg of micro spheres in 500 L ofF12 media (n=6 per group tested).
All animal procedures were performed under the guidelines of the Institutional
Animal Care and Use Commttee of the University of Massachusetts Medical School.
Mice were sacrificed at 2 , 4 , and 8 weeks by anesthesia overdose and samples were
harvested.
Sample Analysis
Upon harvest, the fibrous capsule was removed from each sample. The sample was
first weighed and then cut in thirds. One-third of the sample was digested with 0. 14 mg
papain (Sigma Chemical Company) for 16 hr at 60 C. Papain digested samples were
subjected to biochemical analysis for cell number and proteoglycan content. A second
third ofthe sample was fixed in 10% formalin buffer. The fixed sample was embedded
in paraffm and sectioned. Sections were stained with safranin-O. Unstained sections
were probed for collagen tye I and tye II by immunohistochemistry, as described
below. The last third ofthe sample was digested to extract the collagen molecules from
the tissue and collagen II content was determed by ELISA as described below.
DNA Quantifcation
DNA quantification was performed as described. Briefly, papain digested samples
mixed with phenol-chloroform-isoamyl alcohol (Sigma Chemical Co. , St. Louis , MO).
DNA was extracted and content was read by spectrophotometry at 260 nm and the purity
was determined by the 260/280 ratio. A known number of chondrocytes was used as a
standard for calculation of cell number.
Proteoglycan Content Analysis
Papain digested samples were analyzed for glycosamioglycan (GAG) content using the
DMM-dye binding assay.77 Briefly, 50 J.L of papain digested sample was incubated
with 2 mL ofDMM-dye and the reaction was observed on a spectrophotometer at 525
, with shark chondroitin sulfate (Sigma Chemical Company) used as a standard.
Immunohistochemistr
Detection of collagen tyes I and II was achieved by immunohistochemical staining
as described. Briefly, unstained paraffm sections were deparaffmized, rehydrated and
washed in PBS with 0. 1 % BSA. Samples were incubated with 0.3% hydrogen peroxide
and subjected to digestion for 30 mi with 33U/mL bovine testicular hyaluronidase
(Sigma Chemical Company). Sections were incubated with anti-collagen type I (Santa
Cru Biotechnology, Inc, Santa Cruz, CA) or anti-collagen tye II (Chemicon, Temecula
CA) and incubated with anti-IgG biotinylated secondary antibody (Vector Laboratories
Burlingame, CA). Sections were then subjected to avidin-biotin-peroxidase reagent
(Vector Laboratories) and exposed to diaminobenzidine (Vector Laboratories). Sections
were counterstained with 1 % alcian blue for 3 min for collagen tye I staining or 0.02%
fast green for 4 mi for collagen tye II staining. Digital photomicrographs were
obtained using a Nikon TE 200 microscope equipped with a Spot Junior camera (both
from Micro Video Instruments , Avon, MA).
Collagen Extraction and ELISA
Collagen molecules were extracted from the tissue samples using methods described in
the Native Type II Collagen Detection Kit #6009 (Chondrex , Inc. , Redmond, W A).
Briefly, tissue samples were incubated with 3M guanidine in 50 mM Tris-HCl buffer
overnight at 4 C. The tissue was homogenized and the tissue precipitate was collected
and washed with cold water. The precipitate was re-suspended in 800 JlL of 0.5M NaCI
in 50 mM acetic acid and digested with 1 mg pepsin (Worthington Biochemical
Company) for 48 hr at 4 C. After pepsin digestion, 100 JlL of lOx TSB and 0. 1 mg of
pancreatic elastase (Sigma Chemical Company) were added and samples were mixed
overnight at 4 C. Samples were centrifuged and the supernatant was collected.
Collagen Type II ELISA
Collagen content was determined using the Native Type II Collagen Detection Kit #6009
according to the manufacturer s specifications (Chondrex, Inc). Briefly, the capture
antibody was allowed to adhere to the provided plate overnight. The antibody was
removed and the plate was washed with wash buffer. Type n collagen was used as a
standard and 1 00 l of standards and samples was incubated on the plate at room
temperature for 2 hr. Standards and samples were removed, the plate was washed, and
100 l of detection antibody was incubated on the plate at room temperatue for 2 hr.
The detection antibody was removed, the plate was washed, and 50 l of streptavidin-
peroxidase solution was added to the wells and incubated at room temperature for 1 hr.
Upon removal of the streptavidin-peroxidase, the plate was washed and a solution of
OPD chromogen and H 02 Urea was allowed to react in each well for 30 min at room
temperature. The reaction was stopped with 50 l of2.5N sulfuic acid and the plate was
read at 490 nm.
Statistical Analysis
All statistics were performed using Sigma StatTM Statistical Softare Version 2.0. To
detect statistical differences between tissue mass, proteoglycan accumulation or DNA
content, two-way ANOV A tests were performed with post-hoc Bonferroni test for
paIrWISe companson.
Results
PLG micro spheres exhibited tyical release patterns with an initial IGF-I burst
release followed by prolonged release. Most IGF-I microsphere dose samples (0.007%-
0.3%) had consistent release profies beginning with low initial bursts ofless than 9%
and controlled release out to 8 weeks (Figure 16A). In the controlled delivery phase , the
IGF-I in the media of these samples was detected as early as 1 week, with continued
detection out to 8 weeks. In contrast, microspheres with an IGF-I concentration of
0007% exhbited a slightly larger percent release of total effective IGF-I protein during
the initial burst phase and released a smaller percentage oflGF-I at 6 and 8 weeks than
other doses (Figure 16A). When initial burst patterns were analyzed with respect to IGF-
I release, an inverse relationship was observed. Similarly, the amount ofIGF-I released
to the media in the initial burst phase was highest from 0.0007% IGF microspheres and
decreased as the percent IGF-I in the initial system increased (Figure 16B).
Cartilage samples increased in tissue mass over the 8 weeks in vivo. 
significant differences between different dose groups were detected at earlier time points
of2 and 4 weeks. After 8 weeks, sample mass varied significantly with IGF-I dose.
Cartilage formed with micro spheres containing 0.3% IGF-I exhibited the highest tissue
mass (Figure 17A), and these values were signficantly higher than the lowest IGF-
conditions (p-:O.Ol).
Cell content was determined in all samples , but cell number did not vary between
the different IGF-I conditions at any of the time points. Further, cell number was fairly
comparable to the initial cell load of20 xl0 cells at all of the time points in all of the
conditions (Figure 17B).
GAG trends toward a dose response to IGF-I were detected at each time point
although no significant differences could be detected at weeks 2 or 4 (Figure 18A). After
8 weeks in culture, cartilage formed using 0.3% IGF-I micro spheres exhibited
significantly higher GAG content than cartilage from the 0.0007 or 0.007% IGF-
microsphere (p 02). Normalization of GAG density at each time point to samples that
did not receive IGF- , revealed that the most pronounced dose dependent trends were
present after 8 weeks (Figure 18B).
Proteoglycan distribution was assessed using safranin-O staining. Uniform
staining across the tissue section was evident at all time points in all conditions (Figure
19). After week 2 , proteoglycans were not deposited on microspheres and microsphere
integrity was not compromised (Figure 19A-C). The beginnings of micros ph ere
degradation were evident after 4 weeks in all samples (19D-F), but staining on
microspheres differed. In samples formed from 0% through 0.07% IGF- , micro spheres
exhibited slight staining for proteoglycan deposits (Figure 19D E and data not shown). In
contrast, evidence of GAG deposition on micro spheres appeared to be increased in 0.3%
samples. Moreover, these samples indicated increased chondrocyte migration into the
micro spheres (Figure 19F). After 8 weeks, proteoglycan staining was uniform actoss all
samples after 8 weeks and detection of microsphere remained was diffcult to detect
(Figure 19G-I). Staing across these samples appeared most intense in cartilage formed
with micro spheres containing 0.3% IGF-I at all time points (Figure 19C I), whereas
cartilage formed using other doses oflGF-I or no IGF did not vary in intensity (Figure
19A, H).
Dose responses to IGF-I were detected at weeks 2 or 4 , but after 8 weeks in
culture a well defined trend in dose response was evident. After 8 weeks, samples
receiving the highest amounts ofIGF-I exhibited increased collagen tye IT content, and
cartilage formed with 0.3% IGF-I micro spheres had significantly higher 
collagen content
than the lowest IGF-I doses (p':0. 02) (Figure 20A). When collagen tye IT per wet
weight was normalized to data from samples without IGF-I, analyses indicated that
stimulatory increases in collagen tye II were highest at week 2 but gradually decreased
over the 8 weeks (Figure 20B).
Collagen content was also detected via immunohistochemistry for collagen tye I
or collagen tye IT. All samples stained negative for collagen tye I at each time point
(Figure 21A,B) and positive for collagen tye n at all time points (Figure 21C-F and data
not shown). After 8 weeks, a gradient of staining intensity in cartilage sections with
differing IGF-I micro spheres was detected. Specifically, as the percentage ofIGF-
I in
the system increased, cartilage sections exhibited stronger positive staining for collagen
tye n (Figure 21C-F).
Discussion
Prior work has independently demonstrated PLG micro spheres as a scaffold for
tissue engineering and as a vehicle for controlled release of growth factors. 
This study
demonstrates, for the first time to our knowledge , that PLG micro spheres can be used as a
simultaneous tissue engineering scaffold and vehicle for controlled growth factor
delivery. Further, this study demonstrates long-term enhancement of chondrogenesis by
controlled release oflGF-I doses in vivo.
Protein release via controlled delivery is an important concept for tissue
engineering, as exogenous delivery may be limited by short protein halflives
90 or
interactions with binding proteins and diffusion through ECM. Furher, administering
growth factor directly in vivo would require multiple deliveries, possibly through intra-
articular injection92 or topical application.93 Controlled delivery of growth factor offers a
viable alternative and an easy delivery model for the inclusion of growth factors for
repair by tissue engineering.
Determining release kinetics is a necessary first step in evaluating the
effectiveness of controlled delivery. Typical release patterns from micro spheres or
microparticles have indicated a bi-phasic release profie.
94 In the first phase
referred to as initial burst, immediate release occurs by diffusion of growth factor
tethered to the surface of the microsphere. The second phase of release results in
sustained delivery of growth factor attributed to polymeric degradation, and the length of
this phase can be controlled by the properties of the polymer.
Much work has been done to lower the initial burst exhibited in controlled release
studies, as significant early loss of protein wil decrease the amount of protein available
for sustained release. Work to control initial burst has suggested that the addition of
excipient factors may lower initial burst in some systems.
74 However
, this study did not
require the addition of excipient to control initial burst, and results indicated that initial
bursts oflGF-I from PLG microsphere fell between 4- 13%. The release profies from
microspheres of the various IGF-I doses suggested a trend that initial burst decreased
with increasing IGF-I dose. This relationship between intial burst and IGF-I dose
although interesting, was not determined for statistical significance and would bear
further investigation in order to draw any more conclusions.
Previous studies have demonstrated prolonged IGF-I release out to 4 weeks in an
in vitro drug delivery study47 and out to 2 weeks in a tissue engineering application
?5 In
this study, IGF was detected out to 8 weeks. Sustained release profiles for this study
indicated phase n release initiating at 1 week and steadily increasing to peak release at 6
weeks , with continued detection after 8 weeks. While total protein released after 8 weeks
fell between 65-75% of the initial IGF-I in the system for most doses, virtually complete
protein release from micro spheres has been demonstrated in micro spheres fabricated
using the ProLease(! process 46 suggesting that controlled release oflGF-I in our system
may continue beyond 8 weeks.
In analyzing these samples by histology, the observed degradation trends ofthe
micro spheres in IGF-I samples were fairly consistent with previous results . Typically
for ProLease(! micro spheres made with 50 kDa polymer, evidence of micro sphere
degradation was not observed before 4 weeks (Chapter n ll. Similarly, matrix
deposition in this study remained excluded from microspheres at 2 weeks, and after 8
weeks matrix covered the majority of microsphere area. However, noticeable differences
were detected at 4 weeks, as variations in matrix deposition were exhibited. Specifically,
degradation had occurred in many of the micro spheres in all samples , but matrix
deposition on micro spheres was markedly higher in 0.3% IGF-I samples. Two possible
explanations exist for this observation. First, as IGF-I diffsion can be stuted by
interactions with matrix molecules such as IGF binding proteins
91 cells closest to the
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microsphere may come into contact with more IGF-I than chondrocytes more distant
from microspheres. Second, IGF-I has been implicated in chemotactic increases in
meniscal fibrochondrocytes and chondrocyte motility. 96 Subsequently, higher IGF-
doses may increase the stimulation of chondrocyte migration into microsphere areas
allowing them to make and deposit more matrix in these locations.
Similar to microsphere degradation patterns , the extent oftissue and matrix
accumulation was consistent with release profies. Cartilage samples increased in tissue
size and matrix deposition at 2 and 4 weeks , but the most pronounced effects were
exhibited at 8 weeks for each dose, which is likely an effect from IGF-I released at 6
weeks. At early time points (2 and 4 weeks) a trend toward IGF-I dose-dependent
response was displayed in total matrix accumulation, yet no significant differences were
detected. After 8 weeks, however, a pronounced dose-dependent effect from IGF-I was
exhibited, with the highest dose oflGF-I correlating with the highest mass, GAG
accumulation and collagen content. Similarly, these effects were demonstrated by
staining intensity for proteoglycans (Figure 19) and collagen tye IT (Figure 21), as
sections from 0.3% IGF cartilage exhibited the deepest stain.
Although overall content detection demonstrated increased GAG and collagen
tye IT accumulation over 8 weeks (Figure 18 and Figure 20) and subsequent
normalization ofthese data to 0% IGF-I samples also exhibited increases in overall
content, analysis of normalized densities ofproteoglycan or collagen tye II (Table 6)
suggests differential regulation of these matrix molecules. Analysis of matrix
accumulation to determine the maximum amount of stimulation and the dose necessary to
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elicit half maximal response (EDso) indicated that stimulation of collagen tye n was
maximal after 2 weeks, but this stimulation consequently decreased at 4 weeks and again
at 8 weeks (Table 6). EDso was also higher at 8 weeks , indicating that more IGF-I was
required to elicit an effective response. In contrast, stimulation of GAG density was
miimal at 2 weeks , but increased with time (Table 6), while EDso decreased by a factor
of 100 from 2 to 8 weeks. The overall fmdings of dose-dependent increases in GAG and
collagen type n content in this study are consistent with matrix molecule analysis of other
studies where intact cartilage or tissue engineered constructs were subjected to IGF-
68 However
, no suggestion of differential regulation of collagen and proteoglycan
accumulation has been reported in these studies. IGF-I control of matrix molecules is
believed to be at the level of transcription. 
163 However
, in this study we looked at the
effective accumulation of translated product; thus an understanding of the transcript
levels ofthese matrix molecules in a controlled release system may give insight into this
phenomenon of differential regulation.
Another factor to be considered in a controlled release scaffold system is the
effective dose of growth factor, and tyical effective doses oflGF-I for tissue engineering
have ranged between 10 ng/mL and 300 ng/mL,z4
67 As the controlled release system
does not deliver consistent amounts of protein over a given time period, the effective
doses may be different from exogenous delivery concentrations used in other studies.
Therefore , we evaluated a range oflGF-I doses spanng roughly 3.5 orders of
magnitude. The different IGF-I doses all increased tissue mass and GAG and collagen
accumulation over the duration of the study. However, dose-dependent increases in
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tissue components suggested that the dose eliciting the highest tissue and ECM
accumulation was 0.3% IGF , corresponding to 48 Ilg of total initial protein. Although
physiological levels ofIGF-I have been shown to be effective in vitro, supraphysiologic
levels ofIGF-I do not have negative effects and can stil stimulate matrix growth.
Furher, in a controlled release system, high levels of growth factor delivery may be
needed for a maximal stimulatory effect as IGFBP binding or diffusion oflGF away from
the cartilage implant may impact the effectiveness of the protein by making it unavailable
to the IGF receptor.
Although the effective dose may be different for a controlled release system, the
doses used in this study demonstrate consistency with previous studies that have shown
dose-dependent responses to IGF-I stimulation of extracellular matrix molecule
synthesis. However, there are varying reports on the effects ofIGF-I on cell
proliferation. Some studies have demonstrated increases in DNA content
60 while others
have not seen enhanced DNA synthesis with IGF-I supplementation
?4 Our data was
found to be consistent with studies that do not demonstrate dose-dependent effects on cell
proliferation.
Overall, this study demonstrates long-term, effective controlled release oflGF-
protein from PLG microspheres. The controlled release ofIGF-I increased tissue and
ECM accumulation in a dose-dependent manner. Thus , controlled release of proteins
offers an effective and easy means of incorporating growth factors into a tissue
engineering design with applications for enhanced matrix and tissue output through
prolonged and controlled exposure of cells to growt factors.
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Table 5. Total IGF-I protein loaded for each dose condition. PLG microsphere with a
1 % IGF-I load were fabricated using the ProLeaseCI process. Loaded and unloaded
micro spheres were mixed in different ratios to obtain a range oflGF-I effective loads
between 0 and 0.3% IGF-I. Total protein content in 16 mg ofPLG micro spheres are
given, and total amounts oflGF-I released at each dose was normalized to sample mass at
8 weeks to give an understanding oflGF-I doses.
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Figure 16. Release profies were consistent between different doses ofIGF-I released
from PLG micro spheres with loads ranging from 0.0007% to 0.3% (g oflGF-I per g of
micro spheres ). Microspheres were incubated in vitro in media and the supernatant was
collected at time points between 0 and 56 days. IGF-I concentration in the media was
detected by ELISA and normalized to total IGF-I loaded in the micro spheres. A. IGF-
release profile of each dose over 8 weeks indicated bi-phasic release patterns.
Supernatant concentrations from 0 days correlated to initial burst, while samples take
from 4 hours to 56 days indicated the sustained release phase. B. Amount ofIGF-
released in initial burst decreases with increasing IGF-I dose. IGF-I concentrations from
o days (initial burst samples) were plotted against IGF-I dose.
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Figure 17. Tissue engineered cartilage responded to controlled release oflGF-
Controlled release oflGF-I induced a dose-dependent increase in tissue mass at all time
points (A), but not cell content (B). n=6 for all groups.
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Figure 18. Biochemical analysis ofIGF-I effects on proteoglycan content in tissue
engineered cartilage. DMM dye was used as a colorimetric readout for proteoglycan
content. A. Controlled IGF-I release increased proteoglycan content over time in a dose-
dependent manner at each time point, with samples receiving 0.3% IGF-I exhibiting the
highest GAG content after 8 weeks. B. GAG density (GAG/ tissue wet weight)
normalized to samples without IGF-I was highest at 8 weeks in all samples.
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Figure 19. Proteoglycan staining intensity increased with IGF-I dose. Cartilage sections
stained with safranin-O from 2 week samples, 0% (A), 0.07% (B), or 0.3% (C), or from 4
week samples , 0% (D), 0.007% (E), 0.3% (F), indicated the deepest staining in 0.3%
IGF-I sections at each time point. No differences in staining intensity were detected at
these time points for lower doses oflGF-I and samples without IGF-I. At 4 weeks
samples receiving controlled release oflGF-I exhibited increased matrix deposition onto
the microspheres , with micro spheres from 0. 3% samples exhibiting the most matrix
deposition. (Matrix deposition on the micro spheres at 4 weeks is indicated by yellow
arrowheads). Cartilage sections from 8 week samples , 0% (G), 0.02% (H), and 0.3% (I),
exhibited increased staining intensity with increasing IGF-I dose. All pictures are
magnified 200x.
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Figure 20. IGF-I induced dose-dependent increases in collagen tye n content. ELISA
was used to determine total collagen type n in all samples, as described in materials and
methods. A. IGF-I induced dose-dependent increases in total collagen tye n
accumulation at all time points. The most pronounced dose-dependent effects were
observed at 8 weeks , with the highest collagen tye n content found in 0.3% samples. B.
Collagen type IT density (collagen/wet weight) normalized to samples without IGF-I at
each time point indicated dose-dependent increases in collagen tye n density only at 2
weeks. After 4 or 8 weeks, collagen density did not differ by dose or by the addition of
IGF-I in the system.
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Figure 21. Imunohistochemical staining for collagen tyes I and IT. All samples
indicated were negative for collagen type I, as indicated by blue, at 2 weeks (A) or 8
weeks (B) and positive staining for collagen tye IT, as indicated by brown (C-F).
Samples stained for collagen tye IT at 8 weeks, 0% (C), 0.0007% (D), 0.02% (E), and
0.3% (F), indicated dose-dependent increases in staining intensity. All pictures are
magnified 100x.
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14. 1.47 0.27388 00098
17. 01222 00085
21. 3.46 00314 00154
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Table 6. Differential regulation of matrix accumulation by controlled release oflGF-
GAG and collagen type IT content at 0.3% IGF-I increased at each time point, however
the relative stimulation of GAG and collagen tye IT, as normalized to 0% IGF-
indicated differential regulation. The effective dose necessary to elicit 50% maximal
response (EDso) at each time point was calculated.
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CHAPTER V
UTILITY OF PLG MICROSPHERES CONTAIING IGF -I FOR IN
VITRO CARTILAGE TISSUE ENGINERIG
Summary
PLG micro spheres can be used as a scaffold for cartilage tissue engineering and
have been used in vivo as a simultaneous growth factor delivery vehicle. This study
demonstrates the utility of controlled release oflGF-I from PLG micro spheres on in vitro
chondrogenesis and that this method can be used as an alternative delivery method to
exogenous IGF-I addition in cartilage tissue engineering designs. We demonstrated that
IGF-I induced a dose-dependent increase in both GAG and collagen tye n, but no dose-
dependent changes were exhibited in tissue mass or cell number. Moreover, the effective
dose for enhanced tissue formation was 0.02% IGF-I. At IGF-I effective loads higher
than 0.02%, a decrease in GAG and collagen tye n accumulation was observed. All
tissue sections exhibited IGFBP-2 and IGFBP- , which could playa role in the decreased
ECM accumulation detected at the highest IGF-I doses.
Introduction
The dual role ofPLG micro spheres as a polymer scaffold for cartilage tissue
engineering and a simultaneous delivery vehicle for the growth factor IGF-I in vivo has
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been presented. However, optimal scaffolds for cartilage tissue engineering wil have
utility both in vivo and in vitro. Understanding the nature of the in vivo environment is
obvious, as these systems wil replace tissue defects caused by trauma, age degeneration
or disease. However, in vitro culture conditions allow for the identification of specific
factors that may affect chondrogenesis without confounding effects that can result from
interactions with the host environment. In vitro evaluation of chondrogenesis is
particularly important in a simultaneous controlled delivery and scaffold system, as it
permits the study of many variables that can affect cartilage regeneration including the
effcacy of growth factor release and the actions of the growth factor itself.
Drug delivery by PLG micro spheres is known to be affected by many parameters.
Microsphere size 97-100 variations in the fabrication process, 101, 02 or modifications in
parameters that influence polymer degradation 100 103 have all been demonstrated to
affect drug delivery. Such parameters may exacerbate differences in drug delivery
patterns under in vitro or in vivo conditions, and in fact one such parameter, microsphere
degradation, has been shown to differ under these culture conditions; micro spheres
degrade roughy 2- fold slower in vitro.23 Drug release in such systems follows a biphasic
cure, with the second phase of drug release attibuted to microsphere degradation.
The impact of microsphere degradation in the in vitro environment could prolong the
release oflGF-I to chondrocytes , which may translate into changes in cartilage matrix
accumulation.
In addition to changes on drug release by the in vitro environment, the actions of
the delivered growth factor must be understood. In cartilage biology, in vitro evaluation
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becomes particularly important as it involves complex tissue homeostasis maintained by
a balance of growth factors that can induce similar effects. Growth factors such as IGF-
and TGF- stimulate the synthesis ofproteoglycan and collagen molecules
6o and
FGF, IGF-I and TGF- also increase cell proliferation.
lo3 Not only have multiple
growth factors been shown to present similar stimulation of extracellular matrix (ECM)
proteins , but feedback mechanisms can also be activated by multiple growth factors. For
instance , both TGF- and IGF-I can increase the concentration oflGFBPs in the
tissue 104 105 and the increase in IGFBP production wil subsequently elicit effects on IGF-
I signaling. In some instances this feedback can inibit IGF-I from binding to its receptor
or faciltate IGF-I signaling in cells. 
57 While it is difficult to understand the overlapping
and duplicated actions of these growth factors in vivo, in vitro culture can be used to
defme the actions of a single factor and decouple its mediation of cartilage repair.
We have previously shown that PLG microspheres can be used for cartilage tissue
engineering as a moldable scaffold in vitro. These cartilage tissue disks maintain
thickness and shape, as well as increase the overall matrix and tissue accumulation. 
this study, we expected that PLG micro spheres could be used concurrently as both a
scaffold and delivery vehicle to form shaped cartilage in vitro.
Materials and Methods
Cell Culture
Chondrocytes were isolated from the articular cartilage of calf gleno-humeral joints
of2- 10 day old calves (Research 87 , Hopkinton, MA) using 0.3% tye IT collagenase
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(Worthington), as previously described. After 16 hr of collagenase treatment at 37
isolated chondrocytes were filtered through a 180 /-ID filter to remove any undigested
cartilage particles , washed several times with PBS, and cells were resuspended in Ham
F12 media supplemented with 1% ascorbic acid and 10% FBS.
IGF-I protein preparation
To prepare the protein for microsphere encapsulation, recombinant human IGF-
protein (PeproTech, Inc, Rocky Hil , NJ) was dissolved in 100 mM solution of acetic acid
for a 1 mg/mL solution. The protein solution was then sprayed through a sonic nozzle
over liquid nitrogen, transferred to - C for nitrogen evaporation, and lyophilized.
Microsphere Preparation
PLG was obtained form Alkermes, Inc. PLG microspheres were fabricated using the
ProLease(S process, as described. Briefly, 50:50 lactide:glycolide polymer with a 50
kDa molecular weight and lyophilized IGF-I protein was dissolved in methylene chloride.
This solution was atomized over a bed of liquid nitrogen layered on top of frozen ethanol.
The temperature of the system was then maintained at - C to allow for nitrogen
evaporation and removal of methylene chloride into the ethanol phase (microsphere
curing). The resulting micro spheres (loaded micro spheres ) were filtered and then
lyophilized to remove residual ethanol, and fmally sieved to obtain the desired range of
particle sizes. Microspheres of the same polymer tye were prepared without IGF-
(unloaded micro spheres) using the process above.
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IGF-I load
As prepared, micro spheres had a 1 % IGF-I load. To obtain the desired dosage of
IGF- , loaded microspheres and unloaded microspheres were mixed at different
concentrations (Table 7).
IGF-I Release
Microspheres at varying IGF-I concentrations were incubated in vitro for up to 56
days in Ham s F12 media with 0.3% carboxymethylcellulose (Sigma Chemical Company,
St. Louis , MO). At each time point, media was collected and replaced with fresh media.
Media was assayed for IGF-I content using the Human IGF-I Quantikine ELISA
kit according to the manufacturers specifications (R&D Systems , Inc, Mineapolis , MN).
IGF-I standards and collected media were incubated on an ELISA plate pre-coated with
mouse monoclonal IGF-I antibody for 2 hr at 4 C. Unbound samples were washed from
plate and the plate was incubated with an IGF-I polyclonal antibody conjugated to
horseradish peroxidase at 4 C. Excess secondary antibody was washed from the plate
and wells were incubated with hydrogen peroxide/chromogen for detection ofIGF-
Optical densities were read at 450nm.
"''''
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Culture Conditions and Implantation
Chondrocytes, at a density of 80 x 10 cells/mL were mixed with an equal volume of
PLG micro spheres, at a concentration of 64 mg/mL. The microsphere-chondrocyte
suspension was incubated for 4 hrs at 37 C in a shaker incubator to allow for chondrocyte
attachment to the microspheres.
For in vitro culture , the wells of a 12-well plate were covered with a surface layer of
5% agarose to prevent cell adhesion to the bottom ofthe well , and a cylinder measuring
1 cm in diameter was placed in the well. Agarose solidification sealed the cylinder to the
well. Chondrocytes and micro spheres were delivered as a 500 ilL volume to the
cylinders. Each delivery contained 20 x 10 cells and 16 mg of micro spheres in 500 f.L
ofF12 media (n=3-6 per group tested).
Sample Analysis
Upon harvest, each sample was first weighed and then cut in thirds. One-third of the
sample was digested with 0. 14 mg papain (Sigma Chemical Company) for 16 h at 60
Papain digested samples were subjected to biochemical analysis for cell number and
proteoglycan content. A second thrd ofthe sample was fIxed in 10% formalin buffer.
The fixed sample was embedded in paraffm and sectioned. Sections were stained with
safranin-O. Unstained sections were probed for collagen tye I and type n by
immunohistochemistry, as described below. The last third of the sample was digested to
extract the collagen molecules from the tissue and collagen n content was determined by
ELISA as described below.
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DNA Quantifcation
DNA quantification was performed as described. Briefly, papain digested samples
mixed with phenol-chloroform-isoamyl alcohol (Sigma Chemical Co. , St. Louis , MO).
DNA was extracted and content was read by spectrophotometry at 260 nm and the purity
was determined by the 260/280 ratio. A known number of chondrocytes was used as a
standard for calculation of cell number.
Proteoglycan Content Analysis
Papain digested samples were analyzed for glycosamioglycan (GAG) content
using the DMM-dye binding assay . Briefly, 50 f.L of papain digested sample was
incubated with 2 mL ofDMM-dye and the reaction was observed on a
spectrophotometer at 525 nm, with shark chondroitin sulfate (Sigma Chemical Company)
used as a standard.
Collagen Immunohistochemistr
Detection of collagen tyes I and II was achieved by immunohistochemical staining
as described. Briefly, unstained paraffm sections were deparaffInized, rehydrated and
washed in PBS with 0. 1 % BSA. Samples were incubated with 0.3% hydrogen peroxide
and subjected to digestion for 30 min with 33U/mL bovine testicular hyaluronidase
(Sigma Chemical Company) and blocked with 1. 5% normal rabbit serum (Vector
Laboratories, Burlingame, CA). Sections were incubated with a 1 :50 dilution of anti-
collagen tye I (Santa Cruz Biotechnology, Inc , Santa Cruz, CA) for 48 h at 4 C or a 1:10
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dilution of anti-collagen tye II (Chemicon, Temecula, CA) for 2 hr at room temperature
washed, and incubated with a 1:200 dilution ofanti-IgG biotinylated secondary antibody
(Vector Laboratories) for 30 mi at room temperature. Sections were washed and
subjected to avidin-biotin-peroxidase reagent (Vector Laboratories), washed, and exposed
to diaminobenzidine (Vector Laboratories) for 2 min. Sections were counterstained with
1 % alcian blue for 3 min for collagen tye I staining or 0.02% Fast Green for 4 mi for
collagen tye II staining. Digital photomicrographs were obtained using a Nikon TE 200
microscope equipped with a Spot Junior camera (both from Micro Video Instruments
Avon, MA).
Collagen Extraction
Collagen molecules were extracted from the tissue samples using methods described in
the Native Type II Collagen Detection Kit #6009 (Chondrex, Inc. , Redmond, W A).
Briefly, tissue samples were incubated with 3M guanidine in 50 mM Tris-HCl buffer
overnight at 4 C. The tissue was homogenized and the tissue precipitate was collected
and washed with cold water. The precipitate was re-suspended in 800 
L of 0.5M NaCI
in 50 mM acetic acid and digested with 1 mg pepsin (Worthington Biochemical
Company) for 48 hr at 4 C. After pepsin digestion, 100 L of lOx TSB and 0. 1 mg of
pancreatic elastase (Sigma Chemical Company) were added and samples were mixed
overnight at 4 C. Samples were centrifuged and the supernatant was collected.
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Collagen Type II ELISA
Collagen content was determined using the Native Type II Collagen Detection Kit #6009
according to the manufacturer s specifications (Chondrex, Inc). Briefly, the capture
antibody was allowed to adhere to the provided plate overnight. The antibody was
removed and the plate was washed with wash buffer. Type II collagen was used as a
standard and 1 00 l of standards and samples was incubated on the plate at room
temperatue for 2 hr. Standards and samples were removed, the plate was washed, and
100 l of detection antibody was incubated on the plate at room temperature for 2 hr.
The detection antibody was removed, the plate was washed, and 50 l of streptavidin-
peroxidase solution was added to the wells and incubated at room temperature for 1 hr.
Upon removal of the streptavidin-peroxidase, the plate was washed and a solution of
OPD chromogen and H Urea was allowed to react in each well for 30 min at room
temperature. The reaction was stopped with 50 1 of 2.5N sulfuric acid and the plate was
read at 490 nm.
IGFBP Immunohistochemistr
Unstained paraffm sections were deparrafmized for 5 mi by two separate incubations
with xylene. Samples were then rehydrated in 2 washes for 2 mi each with 100%
ethanol, 95% ethanol, and 80% ethanol , followed by 3 washes with PBS/O. l % BSA for 5
min each. Samples were incubated with 0.3% hydrogen peroxide and subjected to
digestion for 60 min with 0.02U/mL chondroitinase ABC (Sigma Chemical Company)
and blocked for 60 min with 1.5% normal goat serum (Vector Laboratories). Sections
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were incubated with a 1 :50 dilution of anti-IGFBP-2 (Upstate Biotechnology) or anti-
IGFBP-6 (GroPep, Inc. , Adelaide, South Australia) or an antibody:antigen complex for 2
hr at room temp. Antibody:antigen complexes were made 1 hr prior to incubation with
sections and allowed to sit at room temperature during this time. To block IGFBP- , the
antibody:antigen complex was made using IGFBP-2 protein (GroPep, Inc.) in lO-fold
excess of anti-IGFBP-2 by volume, and to block IGFBP-6, the antibody:antigen complex
was made using 12 f!g IGFBP-6 protein (GroPep, Inc.) to 2.5 f!g anti-IGFBP-6. Sections
were washed and incubated with a 1 :200 dilution of anti-IgG biotinylated secondary
antibody (Vector Laboratories) for 30 min at room temperatue. Sections were washed
and subjected to avidin-biotin-peroxidase reagent (Vector Laboratories), washed, and
exposed to diaminobenzidine (Vector Laboratories) for 2 min. Sections were
counterstained with Hematoxylin QS (Vector Laboratories) for 45 sec, and the
counterstain was rinsed off with deionized water for 10 sec. Digital photomicrographs
were obtained using a Nikon TE 200 microscope equipped with a Spot Junior camera
(both from Micro Video Instruments).
Statistical Analysis
All statistics were performed using Sigma Stat
IM Statistical Softare Version 2.0. To
detect statistical differences between tissue mass, proteoglycan accumulation or DNA
content, two-way ANOV A tests were performed with post-hoc Bonferroni test for
paIrWISe companson.
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Results
IGF-I release was evaluated in microspheres with 0.0007% to 0.03% IGF-I. Total
protein loads ranged from 0-48 g oflGF-I in the system (Figure 21A). Microspheres
containing 0.007% to 0.3% IGF-I exhibited 65-75% growth factor release, while
0007% IGF-I microspheres released almost 100% ofthe growth factor (Figure 22B). 
all cases , however, 50% of the IGF-I in the system was released by 29 to 38 days (Figure
22A).
Cartilage tissue was formed in the absence oflGF-I or in the presence oflGF-
either by exogenous delivery or controlled delivery. In most cases, the cartilage tissue
maintained the disk-like shape provided by the mold, as demonstrated in our previous in
vitro studies. However, at the two week time point, samples formed from PLG
micro spheres with 0.0007% IGF-I did not solidify into a disk and broke apart upon
removal from the mold, and thus these samples could not be analyzed.
Cartilage growth supplemented with 30 ng/ml IGF-I by exogenous delivery or
02% IGF-I by controlled release overall formed similar cartilage tissue and both were
significantly different from samples that did not receive IGF-I after 8 weeks for most
parameters. Samples treated with exogenous IGF-I increased tissue mass over 8 weeks of
cultue, while samples formed with controlled delivery oflGF-I or no IGF-I maintained
relatively constant levels oftissue mass (Figure 23A). No differences in cell number
were detected between any groups (Figure 23B). In addition, more proteoglycans (Figure
23C) and total collagen IT (Figure 23D) were accumulated in samples receiving IGF-I by
both delivery methods when compared to samples that did not receive IGF-I. However
131
no differences in these parameters were observed after 8 weeks between samples
receiving IGF-I by exogenous addition or controlled delivery.
Samples receiving IGF-I through controlled delivery were then analyzed at IGF-
doses from 0%- 7% of the total microsphere mass. In many of these samples tissue
mass peaked by week 4 and by 8 weeks did not vary. No dose response to tissue mass
was observed at any ofthe time points taken (Figure 24A). Similarly, cell number did
not respond to IGF-I in a dose dependent maner, and overall, cell number remained
unchanged throughout the study (Figure 24B).
However, dose responses to IGF-I were observed in samples analyzed for
proteoglycan accumulation (Figure 25A). Without IGF-I or at the 0.0007% oflGF-
proteoglycan accumulation was low and remained relatively unchanged through the 8
week study. Although all samples exhibited increased GAG content after 8 weeks
(p-C0.05), dose responses to IGF-I were only detected in samples receiving up to the
02% IGF-I (p-cO.OOl), after which a decrease in GAG content was observed in 0.07%
and 0 7% IGF-I samples when compared with the 0.02% IGF-I group (Figure 25A). In
contrast, GAG density remained relatively unchanged at each time point. However
samples receiving 0.02% IGF-I exhibited higher GAG density than other groups after 8
weeks (Figure 25B).
Samples were stained with safranin-O to analyze the proteoglycan distribution
across the tissue. At 2 weeks, samples receiving IGF-I through exogenous delivery
(Figure 26A) or controlled release (Figure 26B) exhibit homogenous staining for
proteoglycans across the tissue sections. Samples that did not receive IGF-I had strong
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safranin-O staining, but this staining was interspersed (Figure 26C). After 8 weeks
samples receiving IGF-I by either means continued to display homogenous staining for
proteoglycans, but slight staining on the micro spheres (Figure 26D, E). However
samples without IGF-I continued to demonstrate interspersed and disconnected tissue
staining patterns (Figure 26F).
Detection of collagen tye II accumulation suggested a dose response to IGF-I at
each time point, with the most defmed dose response at 8 weeks. After 2 or 4 weeks
samples receiving 0.02% or 0.07% IGF-I presented the highest collagen levels.
However, at the 8 week time point, a shift in the dose response to IGF-I was observed.
Samples increased in collagen tye II content with the highest content exhibited in 0.02%
IGF-I samples , but the collagen tye II content decreased at higher doses of 0.07% and
7% (Figure 27A). In addition, collagen content remained relatively unchanged after 2
or 4 weeks , but exhibited increased collagen densities in all groups after 8 weeks, with
samples receiving 0.02% IGF-I demonstrating the highest collagen density (Figure 27B).
Cartilage sections were immunostained for collagen tye I or collagen tye II.
Samples immunodetected for collagen tye II exhibited homogenous positive staining,
indicated by the brown coloration (Figure 28A, C). Samples receiving IGF - I through
controlled or exogenous delivery exhibited negative staining for collagen tye I (Figure
28B), while samples that did not receive IGF-I exhibited slight areas of positive staining
for collagen tye I (Figure 28D).
Imunostaining was also used to detect the presence oflGFBPs in engineered
cartilage. Imunostaining in samples receiving IGF-I suggested the presence of both
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IGFBP-2 (Figure 29A) and IGFBP-6 (Figure 29B), which was indicated by a brown
coloration across the tissue sections. In contrast, samples that were not delivered IGF-
exhibited a few positive areas for IGFBP-2 (Figure 29C) and IGFBP-6 (Figure 29D) that
were interspersed with larger areas staining negative for both binding proteins, indicated
by the purle counterstain.
Discussion
PLG micro spheres have been used in tissue engineering for the controlled release
of growth factors, but have not been utilized in vitro as a simultaneous controlled
delivery vehicle and tissue engineering scaffold. This study demonstrates the use of PLG
micro spheres as both a scaffold and controlled delivery vehicle of growth factor (IGF-I)
for in vitro cartilage regeneration. In addition, this study shows controlled release of
IGF-I from PLG micro spheres dose-dependently enhances cartilage matrix regeneration.
Because of its well-known stimulatory effects on cartilage matrix synthesis
various delivery methods for adding IGF-I to tissue engineering designs exist.
However, many of these delivery methods are arduous, as they require repetitive addition
of growt factor in media changes or manipulation of the chondrocyte by transfection or
transduction. Thus , controlled release of growth factor from a scaffold that can
simultaneously support carilage growth would be desirable. To identify whether
controlled release ofIGF-I provided a substitute delivery method, we compared
developing cartilage that received IGF-I via controlled release , exogenous IGF-I addition
in media, and no IGF-I. After 8 weeks, all samples receiving IGF-I formed more
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cartilage tissue and accumulated matrix to a greater extent than samples without IGF-
In addition, controlled release oflGF-I was as effective as exogenous delivery in forming
tissue and generating matrix. Overall, two differences were detected between groups
with different delivery methods. The first variation was noted in GAG accumulation at 2
and 4 weeks , as samples receiving exogenous delivery significantly amassed more GAG
(p-(0.001). Similarly, previous results (see chapter IV) have demonstrated slower GAG
accumulation at these early time points, with increased accumulation after 8 weeks. The
increased GAG content after 8 weeks seems to correlate with microsphere degradation
and increased IGF-I release. The second difference indicated a more perplexing
variation with regard to significantly higher tissue mass in samples receiving exogenous
IGF-I delivery after 8 weeks (p-(0.001). At this same time point both groups exhibited
equal accumulation of proteoglycans and collagen, and the differences seen may be
attributed to differences in water content. However, dry weights would need to be
evaluated to confIrm this speculation.
Given that controlled release enhanced matrix accumulation and cell content to
the same extent as exogenous delivery, we then wanted to determine the range of
effective doses of controlled release in this system for in vitro cartilage regeneration.
Doses between 0- 7% IGF-I were evaluated, containg total protein loads of up to 48
/-g oflGF-I. Over 8 weeks , between 65 and 100% ofthe IGF-I was released, and up to
32 /-gof protein was delivered. Had these doses been delivered consistently, this would
correlate to up to 333 ng/ml over 8 weeks, which can be related to tyical doses of 10-
300 ng/ml used for exogenous addition, direct injection, or encapsulation ofIGF-
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61 However
, in a controlled delivery system, protein release is dependent on
444647 . 
mIcrosp ere egra atIon an t erel.ore not consIstent over tIme , as Icate m t 
study with the highest concentration oflGF-I being released between weeks 4 and 6.
Dose dependent trends exhibited in matrix accumulation appeared to adhere to
release patterns. At all time points, dose-dependent increases in GAG accumulation were
exhibited, while dose-dependent increases in collagen content was only observed after 8
weeks. However, dose-dependent trends for both collagen and GAG contents were most
pronounced at 8 weeks, which would coincide with the samples receiving the highest
release oflGF-I. In addition, increases in GAG and collagen content followed similar
dose-dependent cures; GAG and collagen levels increased dose-dependently in groups
receiving up to 0.02% IGF- , while at doses higher than 0.02% IGF-I GAG and collagen
contents decreased. Collectively, these data suggest that the most effective doses for
cartilage regeneration are different from those doses found to be stimulatory when added
by exogenous addition or direct injection. Moreover, it has been suggested that in vitro
delivery of supraphysiologic doses oflGF-I do not have a negative effect on
chondrocytes or matrix production 68 but in this system, the highest doses oflGF-
(0.07% or 0.7% IGF-I) did not produce as much matrix as other doses, suggesting
negative effects on matrix production.
The presence of IGFBPs suggests one possible explanation for decreased matrix
content at higher doses. IGFBPs are known to attach to components within the
matrix I07-109 or directly to cell surfaces llO and specifically, in cartilage tissue IGFBP-
localizes around the membrane of the chondrocyte , 1 11 while IGFBP-61ikely binds to
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matrix materials located further from cells and blocks diffusion oflGF- Thus
although IGFBP-2 is found in these engineered tissues, the presence ofIGFBP-6 may
contribute to increased binding ofIGF away from the cell. In this study qualitative
assays were used to demonstrate the presence oflGFBPs in engineered cartilage using
the controlled release system. However, it would be interesting to quantitatively
determine the concentrations of specific IGFBPs relative to other IGFBPs in the tissue to
further understand the paradigm of binding protein location and infuences on IGF-
interaction with chondrocytes.
In addition to IGFBP location, another explanation for the plateau in matrix
molecule content after 8 weeks in the higher IGF-I doses could be that IGF-I itself is
regulates the production of additional IGFBPs. Work has indicated that stimulation of
chondrocytes with IGF-I increases IGFBP content.
105,106 Although the scope ofthis work
did not specifically seek to evaluate delivery concentrations oflGF-I that would stimulate
IGFBP production, the understanding gained from this study suggests that as microsphere
degradation ensues and release oflGF-I increases , doses of 0.07% IGF-I and higher
likely increase IGFBP concentrations. The supposed increase in IGFBP concentrations
likely inibits IGF-I from interacting with its receptor to stimulate increases in GAG and
collagen tye IT content.
Overall, this study demonstrates effective production of engineered cartilage
using PLG micro spheres as both a growth factor delivery system and polymer scaffold
and controlled release oflGF-I offers an alternative method to exogenous protein
delivery, as both delivery methods stimulated matrix accumulation to the same extent.
Moreover, evaluation of cartilage tissue regeneration suggested that 0.02% IGF-
provides the most effective dose for cartilage tissue regeneration.
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IGF Dose
00/0
00070/0
007%
070/0
Total lGF in
system (ug)
112
11.
112
138
ng IGF-I/ml
(8 wk)
11.
117
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Table 7. Total IGF-I protein loaded for each dose condition. PLG microspheres with a
1 % IGF-I load were fabricated using the ProLeaseCI process. Loaded and unloaded
microspheres were mixed in different ratios to obtain a range oflGF-I effective loads.
Total IGF-I protein in the 16 mg ofPLG microspheres is reported for each effective dose
and the total amounts oflGF-I released for each dose was normalized to total media used
over 8 weeks (96 ml media).
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TotalIGF- # of Days
IGF- (ug) released for 50%
dose after 8 weeks Release
00/0
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007% 771 36.
30/0 32. 37.
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Figure 22. Controlled release oflGF-I from PLG microspheres. PLG micro spheres with
a range oflGF-I effective loads were incubated in F- 12 media. At time points between 0
and 56 days , media was removed and replaced with fresh media. IGF-I content in the
media was evaluated using an IGF-I ELISA, as described in materials and methods. A.
Total protein release from micro spheres containing different concentrations oflGF-I was
evaluated out to 8 weeks. Microspheres released between 0.2 and 32/lg oflGF-
depending on the IGF-I dose, with all groups releasing 50% of the protein load around
30-40 days. B. Cumulative IGF-I release from different microsphere groups indicated
that around 70% of the total IGF-I in the system was released by 8 weeks for IGF-I doses
ranging between 0.007% and 0.3% , whereas microsphere doses of 0.0007% released
almost 100% of their contents.
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Figure 23. Controlled delivery oflGF-I offers an alternative to exogenously delivered
IGF-I in cartilage tissue engineering. Cartilage formation was assessed in samples
receiving IGF-I by exogenous delivery, controlled release oflGF- , or no IGF-I delivery
with respect to tissue mass (A), cell number (B), GAG content (C) and collagen tye II
accumulation (D). Tissue mass was increased after 8 weeks only in samples receiving
exogenous IGF-I (A), but by 8 weeks delivery of samples formed using controlled IGF-
release accumulated GAG and collagen tye II to the same extent as samples receiving
exogenous IGF-I (C D). Samples from both exogenous delivery and controlled release
groups formed significantly more GAG and collagen than cartilage that did not receive
any IGF-I (p':0. 001). No differences were detected in cell number between any of the
groups (B). n=3 for exogenous IGF-I samples, and n=6 for IGF-I controlled release
samples and for samples without IGF-
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Figure 24. Controlled release oflGF-I on tissue mass and cell number is not dose-
dependent in vitro. Controlled release oflGF-I on cartilage formation was assessed over
a range of doses (0- 07% IGF-I). The effect ofIGF-I concentration was evaluated for
cartilage tissue mass (A) and cell number (B). No differences in tissue mass at 2 or 4
weeks or in cell number at any time point were observed. IGF-I significantly increased
tissue mass in samples receiving 0.007% or 0.07% IGF-I (p':0. 001) after 8 weeks , but
IGF-I did not induce a dose-dependent increase in tissue mass at this time point.
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Figure 25. Dose-dependent effects ofIGF-I were observed in GAG accumulation. A.
IGF-I induced dose-dependent increases on GAG accumulation at each time point. After
2 or 4 weeks , samples with effective loads of 0.07% accumulated the most GAG. By 8
weeks , a shift in the dose-response cure was observed, where samples receiving 0.02%
IGF-I had the highest GAG content (p.cO.002). Samples receiving doses higher than
02% IGF-I indicated decreased GAG content at 8 weeks (p.cO.001). B. GAG content
was normalized to tissue wet weight, and similar dose-response curves were observed for
GAG density. Samples receiving 0.07% IGF-I exhibited the highest GAG density after 2
or 4 weeks , but at the 8 week time point, samples formed with 0.02% IGF-I effective
loads exhibited the highest GAG density. n=6 for all groups.
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Figure 26. Cartilage sections from 2 week samples (A-C) and 8 weeks samples (D-
were stained with safranin-O as an indicator of proteoglycan deposition throughout the
matrix. The presence of micro spheres, indicated by (s), was clearly detectable in samples
that received exogenous IGF-I (A, D) or controlled release ofIGF-I (B , E), but
micro spheres were difficult to decipher in sections from cartilage tissue formed without
IGF-I. In samples receiving IGF- , matrix deposition appeared homogenous across the
sections as more matrix was deposited onto microspheres (indicated by black
arrowheads). In contrast, at all time points , samples that did not receive IGF-I exhibited a
lack of tissue continuity and sparse matrix deposition. All samples were magnified 200x.
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Figure 27. IGF-I induced dose-dependent increases in collagen tye IT levels. Collagen
tye IT content was evaluated by ELISA, as described in materials and methods.
Collagen tye IT content was evaluated as total collagen tye IT (A) or normalized to
tissue wet weight to obtain collagen type IT density (B). A. Collagen content remained
low at 2 and 4 weeks, with slight dose-responses to IGF-I at these time points. After 8
weeks , total collagen tye II levels followed a more pronounced dose-dependent increase
to IGF-I. Increases in collagen content were observed in samples receiving up to 0.02%
IGF- , after which a decline in total collagen was detected. B. Analysis of collagen
density revealed slight dose-responses to IGF-I at weeks 2 or 4. A more pronounced
dose-response cure was observed after 8 weeks , with the highest collagen density
exhibited in samples receiving 0.02% IGF-I. Although trends were observed, no
statistical differences were detected. n=3 for all groups.
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Figure 28. Samples receiving IGF-I maintain the collagen type II phenotype.
Imunostaining for collagen tye II (A, C) and collagen tye I (B , D) revealed
differences for tissue samples with IGF-I (A, B) or without IGF-I (C , D). All samples
retained their native collagen type II phenotye , as indicated by the unform brown
staining throughout the sections (A , C). Samples receiving IGF-I displayed negative
staining for collagen tye I as indicated by the homogenous blue staining of the tissue
(B). In contrast, cartilage samples formed without IGF-I exhibited some positive brown
staining for collagen tye I, indicated by the black arrowheads (D). All pictures are
magnified 100x.
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Figure 29. IGFBPs are present in tissue engineered cartilage. Imunostaining of 8
weeks sections from samples with (A, B) or without (C , D) IGF-I indicated differences in
staining patterns for IGFBP-2 (A, C) and IGFBP-6 (B , D). All samples receiving IGF-
were positive for both IGFBP-2 and IGFBP- , as indicated by the brown color. In
contrast, IGFBP-2 and IGFBP-6 were less evident in samples that did not receive IGF-
fewer areas of positive staining (indicated by brown and black arrowheads) were
juxtaposed with large areas of negative staining (indicated by purple) for IGFBP-2 and
IGFBP-6. Native cartilage was immunostained for IGFBP-2 (E) or IGFBP-6 (data not
shown) were similar in staining patterns , with positive staining localized around the
chondrocytes. Panel F depicts a tyical engineered carilage section imunostained
without primary antibodies to IGFBP-2 or IGFBP- , which only exhibited evidence of
the negative hematoxylin (purple) counterstain. All pictures were magnified 200x.
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CHAPTER VI
DISCUSSION
The polymer scaffold offers an integral component to the tissue engineering
design, and therefore provides a unique opportity to control the process of tissue
generation. Polymers used as tissue engineering scaffold tyically present a range of
parameters such as strength, durability, or biocompatibility, but can also present
shortcomigs such as lack of control of polymer degradation or little to no support of
cellular attachment. Although much work has been done to circumvent such limitations
little work has been done to investigate the impact of the polymer or the scaffold as an
active component in cartilage tissue engineering. This discussion wil point to the
development and relevance of a novel PLG microsphere system, used as a simultaneous
polymer scaffold and growth factor delivery vehicle, to understand the role ofthe
polymer scaffold in chondrogenesis. Data presented in this body of work suggests that
the polymer and scaffold can be manipulated to incorporate changes that support and
enhance cartilage tissue engineering. Specifically, it was found that polymer and scaffold
changes that slowed microsphere degradation or gradually released IGF-I enhanced
cartilage formation.
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The Presence of a Polymer Scaffold in Chondrogenesis
Many studies in tissue engineering have recognized the value in using a polymer
scaffold for cell attachment and the support oftissue development. In this study, we have
compared cartilage tissue formed from cells alone or from cells and micro spheres, and
overall we have observed more tissue and matrix formation in samples prepared with
microspheres. Moreover, our data suggested that micro spheres preserve space for later
tissue deposition, purportedly by allowing chondrocytes to migrate into the space
occupied by degrading micro spheres to deposit additional matrix. This is in contrast to
tissue formed from cells alone, which exhibit abnormal cell spacing as evidenced by this
study and others when cartilage is regenerated with only chondrocytes.
In this way, the scaffold may also serve in the generation of cartilage with higher
GAG content. Cell spacing can infuence multiple tissue characteristics, including the
cartilage matrix. The ECM of cartilage consists of the pericellular matrix, which directly
surrounds the cell, an intermediary matrix termed the territorial matrix, and an
interterrtorial matrix that is further removed from the cells.2 Thus, it is conceivable that
in tissue exhibiting hypercellularity and a lack of appropriate cell spacing, the overall
amount of pericellular matrix would increase. In turn, multiple scenarios could be
construed. The pericellular matrix is known to contain large amounts of tye VI collagen
and proteoglycans , while the interterritorial matrix provides the bulk of cartilage tissue
principally composed of collagen tye II and aggrecan.2 A shift in these tissue
constituents may result in mechanically inferior tissue. Similarly, increases in
pericellular matrix content may also have effects on matrix remodeling. Recently,
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ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin-like motif) has
been shown to become activated on the cell surface.
lI2 ADAMTS4 degrades
aggregating proteoglycans I13-115 and as such an increased pericellular matrix would
provide a larger proteoglycan pool for susceptibility to matrix remodeling.
In addition to concerns of tissue inconsistencies with native cartilage , the presence
of a polymer scaffold may enhance tissue formation by miimizing oxygen conditions.
Detection of the diffusion of molecules such as oxygen demonstrated a gradient in the
tissue-engineered construct, with the lowest oxygen levels at the center ofthe tissue
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Low oxygen levels have been shown to induce redifferentiation of dedifferentiated
chondrocytes. 85 In addition, high oxygen tensions have been shown to increase GAG
content initially, but low oxygen tensions signficantly increased GAG content over time
when compared to samples with elevated oxygen levels.
85 In this study, all cartilage
samples formed with or without microspheres exhibited similar GAG contents after 2
weeks. However, cartilage formed with cells and micro spheres exhibited an overall
higher GAG content at later time points. Taken together this data suggests that
limitations in oxygen diffsion due to the presence of microspheres, which generate
greater tissue mass and subsequent diffusional distances, may support and generate better
matrix accumulation.
Changes in Polymer and Scaffold Affect Chondrogenesis
The effect of polymer degradation has been an important topic for consideration
in tissue engineerig studies because of potential toxicity of acidic degradation
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products l17 and harml effects on cells.5o Therefore , we evaluated polymer and scaffold
parameters that would slow degradation rate and production of polymer breakdown in the
form of carboxylic acid end fragments. One parameter that we evaluated was
microsphere size, Increasing microsphere size would also provide additional surface area
for cell attachment and degrade slower because they require more hydrolytic events
leading to polymer breakdown and degradation. We found that the size of the
microsphere did not change the amount of matrix accumulated or number of cells that
proliferated. Rather, weak staining for proteoglycans around the larger micro spheres was
detected. It is likely that the weak staining for proteoglycans can be attributed to low pH
since drops in pH do not increase matrix production.
5o Moreover
, larger microsphere
likely retained acidic fragments longer because the diffusional distance for clearance of
these fragments was greater than in micro spheres with smaller diameters. Thus, the
build-up of these fragments leads to a lower pH. It is likely that when the
micro spheres had bioeroded enough to increase pore size , the acidic fragments diffsed
out of the micro spheres in large quantities, which likely had toxic effects on the
production of matrix from the surrounding cells.
Work to control polymer degradation has often included the addition of molecules
that would buffer the acidity of the degrading environment.
23 However
, negative affects
on matrix production were observed in samples that received MgOH2 buffer. It is likely
that large amounts of released buffer led to decreased matrix accumulation, which could
be confrmed by evaluating the release profiles for buffered microspheres, but was not
undertaken in this study. Further, it is unclear whether the buffer induced the cells to
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apoptose or necrose. If the buffer caused the cells to apoptose, it would be important to
understand the potential signaling molecules that are upregulated or activated under these
conditions since apoptosis can be induced by numerous molecules within the signaling
cascade. 1l9
The addition of a hydrophobic cap provides another means to slowing polymer
degradation and limiting the generation of high concentrations of acidic ends. Polymer
capping decreases the rate at which water is absorbed into the polymer23 and generates
fewer acidic ends. In this study, tissue formed from capped polymer exhibited increases
in matrix accumulation and were not inhibited by the generation of acidic fragments
likely because acidic by-products were able to diffuse out ofthe micro spheres faster than
they were produced. Capped micro spheres were designed with polymer that has roughly
the same degradation time as the 50 kDa polymer. While both of these polymers showed
slowed degradation, the addition of a capped end group also increased the hydrophobicity
of the polymer and microsphere, which may preclude cell attachmen and limit matrix
deposition on these microspheres.
Degradation can also be altered by increasing the molecular weight of the
polymer used to form the microsphere. High molecular weight polymers require an
increased number of catalytic events to break down the polymer, fewer acidic by-
products are generated, and the polymer degrades slower than lower molecular weight
polymers.23 In this study, microspheres formed with 50 kDa polymer led to cartilage
tissue with enhanced matrix production and evidence of matrix deposition onto the
microspheres after 8 weeks. Although micro spheres made with 50 kDa polymer
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supported cell attachment and tissue growth seemingly better than other microspheres
used in this study, only two different molecular weight polymers were analyzed. Thus
polymers with a range of molecular weights would provide a better understanding of the
role that molecular weight plays in cartilage formation.
It is clear from these studies that controlling polymer degradation is a significant
issue in cartilage tissue engineering. However, assessment ofthe individual factors that
may affect degradation give an understanding of how specific characteristics, such as
chemistry, size, molecular weight, or buffer, affect cartilage development. This study
marks the begining of the evaluation of such parameters, but there are many more
scaffold features that could inuence tissue development, including pore size and
porosity of the scaffold, that would need to be assessed. The PLG micro spheres used for
tissue engineering offer a plausible system for evaluation of such parameters since
alterations in the polymer or scaffold resulted in similar behavior both in vivo and in
vitro , suggesting that the observed effects can be attributed to the specific modified
parameter.
Chondrocyte Metabolism
Organization of the cartilaginous matrix incorporates multiple proteins and
proteoglycans in an interconnected network, and the sole responsibility of the
chondrocyte is to synthesize and maintain this network. The importance of an organized
and interconnected ECM is evidenced in disease conditions such as osteoarthritis that
presents with joint degeneration and release ofproteoglycan and collagen
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moleculesYO-122 Subsequent loss or low concentrations ofthese molecules leads to
insufficient tissue mechanics and reduced compressive and/or tensile moduli.
123 126 Thus
to determine the viabilty of a novel tissue engineering strategy, the analysis of matrix
content and maintenance of the chondrocytic phenotype is critical.
In this study, a novel cartilage repair strategy using a PLG microsphere scaffold
with the potential for controlled delivery of growth factor, has been evaluated with
respect to matrix development both in vivo and in vitro. Native cartilage tissue exhibited
on average 4-5% GAG per tissue wet weight and 0. 10% collagen tye II tissue wet
2637 127 128 
. . 
weI a ItIon, engmeere cartl age orme un er varymg con ItIons 
demonstrated a range of GAG densities from 1-5% oftissue wet weight and collagen
densities ranging from 0.05-4% oftissue wet weight over a duration of2 to 30
weeks 31,32 127 128 In the curent studies , up to 3.5% GAG density and 0.3%
collagen density has been generated in vivo, while in vitro cultured cartilage displayed up
to 2.2% GAG density and 0.04% collagen density. Overall, our methods produced levels
of collagen and GAG that are consistent with other engineered cartilage models
, serving
to validate the cartilage tissue engineering strategy of a simultaneous scaffold and growth
factor delivery vehicle.
Although the aforementioned results lend promise to the utilty of this novel
cartilage repair method, slight shortcomings in matrix accumulation were observed in
vitro in cartilage samples receiving IGF-I; specifically, low collagen type II accumulation
was exhibited in all samples regardless oflGF-I dose. Collagen synthesis and protein
assembly is a complex process, preceded by transcription ofthe Col2al gene. Upon
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production ofthe collagen molecule, intracellular, self-organization of three al collagen
molecules forms a triple helical molecule with telopeptide regions that require cleavage
prior to ECM incorporation. 129 Although, IGF-I has been demonstrated to upregulate
both collagen mRA and protein levels 130 it is unclear whether the lack of collagen
accumulation can be attributed to changes in chondrocyte metabolism at the level of
transcription or translation, improper collagen assembly, or protein degradation by
collagen specific proteases , such as matrix metalloproteases.
Although IGF-I is a potent cartilage matrix stimulator, matrix accumulation in
vivo is a collective effort of many growth factors. In addition to IGF- , both TGF- and
bFGF have been shown to stimulate matrix production 67 Moreover, some tissue
engineering strategies have taken advantage of using simultaneous or sequential delivery
of multiple growth factors to promote increases in matrix parameters. When TGF- and
IGF-I were used in combination, GAG density was increased as compared to samples
receiving just IGF-I or just TGF- 25 Similarly, chondrocytes expanded with FGF-2 and
subsequent 3-dimensional culture with bone morphogenetic protein-2 maintained
chondrocyte phenotye and exhibited increased matrix accumulation.132 Using a PLG
microsphere scaffold would faciltate simultaneous and/or sequential growt factor
delivery for cartilage tissue engineering. Microspheres can be loaded with different
growth factors and mixed to achieve desired growth factor ratios and release.
Chondrocytes seeded with mixed microsphere populations could receive growth factors
at equal rates of release , or, by varying microsphere parameters , one growth factor could
be released to the chondrocytes prior to release of the second.
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Alternative Methods to Exogenous IGF-I Delivery
The importance oflGF-I in enhancing chondrogenesis is indicated by the multiple
systems designed to incorporate IGF-I into tissue engineering. The addition of
exogenous growth factor 32 is limited by protein half-life
90 and as such
, alternative
delivery methods have been developed. In this study we have implemented sustained and
controlled delivery oflGF-I during neo-cartilage formation. Used in this cartilage tissue
engineering strategy, we demonstrated that controlled delivery ofIGF-I offers a viable
alternative to exogenous growth factor delivery.
Other methods have also been developed to counter limitations on protein half-
life, including gene therapy applications. The amalgamation of tissue engineering and
gene therapy, in its relatively young stage, has been attempted via transfection of primary
articular chondrocytes with a plasmid containing the IGF-I gene for use in regenerating
cartilage tissue.69,70 Transfected chondrocytes transplanted onto articular cartilage
explants formed a layer of tissue on the explant with enhanced GAG synthesis.
addition, increases in GAG stimulation, collagen tye IT content, and the confmed-
compression equilibrium modulus were evident after 4 weeks in cartilage engineered
with IGF-I transfected chondrocytes embedded in PGA scaffolds.
Similarly, ideas for joining gene therapy with tissue engineering have been
approached using naked plasmid DNA embedded in polymer. Current studies have
depended on the migration of cells into the DNA-laden polymer matrix, relying the cells
themselves to ingest the DNA plasmid, a method that has been shown to repair bone
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defects.133 This model likely has applications for polymer matrices pre-seeded with both
DNA and cells , which would potentiate more effcient delivery of DNA and transfection
of the cells given the close proximity of the two constituents. In addition, controlled
DNA delivery from PLG microspheres has also been demonstrated in vitro
134,135 
but as
of yet has not been used to generate engineered tissue. Overall, however, the utility of
genetic manipulation wil be understood by future experiments comparing its effciency
with controlled and sustained protein delivery.
Effective Dose ofIGF-I Differ in Vivo and In Vitro
Given the multitude of literature demonstrating the stimulatory effects of the
growth factor, it was expected and confrmed that controlled delivery oflGF-I enhanced
chondrogenesis. A first step in validating this method for tissue engineering applications
is to evaluate a range oflGF-I doses effective in a controlled release system for relevance
both in vivo and in vitro.
The fact that the effective dose ofIGF-I varies in vivo and in vitro raises
numerous questions about the actions oflGF-I. The most obvious question raised
concerns the discrepancy in effects on matrix production in doses higher than 0.02% IGF-
I. Such inconsistencies could be explained by the diffusion of released IGF-I out of the
developing tissue nodule and into the host tissue in vivo , such that all IGF-I delivered by
controlled release would not act on the developing cartilage tissue. Consistent with this
theory, when PLG micro spheres containing GH were locally implanted in rhesus
monkeys, an increase in serum GH levels , IGF-I and IGFBP-3 levels were observed.
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Thus , it would be important to evaluate the surrounding endogenous tissue for detection
ofIGF-I actions. Further, one might expect that more regular media changes would
ensure that IGF-I did not build up in vitro , enabling any IGF-I that diffsed out of the
tissue to enter back into the construct.
A second question surrounds the role and production oflGFBPs in the engineered
tissue. Because IGF-I has been shown to increase the production ofIGFBPs 106 and in
these studies we have only qualitatively demonstrated the presence oflGFBP-2 and
IGFBP-6 in vitro , quantification of these binding proteins would provide an initial
understanding to the role that IGFBPs in cartilage tissue engineering. Specifically,
comparing the relative concentrations of binding proteins in samples receiving different
doses oflGF-I would enable an understanding as to whether IGFBPs inhibited IGF-
actions at the highest doses in vitro.
An equally plausible explanation for differences in matrix production in samples
generated with the highest IGF-I doses both in vivo and in vitro could be the regulation of
IGFBPs themselves. Proteolysis oflGFBPs has been demonstrated in most IGFBP
family members, which can be attributed to multiple enzyme classes including serine
proteases , matrix metalloproteases and cathepsins.136 There is evidence suggesting that
in some instances, cleavage of the IGFBP releases intact IGF-I from the complex.137 As
these proteolytic enzyes are likely more abundant in vivo because ofthe additional
supply from the host, a balance of complex cleavage and IGF-I release may be faciltated
in vivo allowing the high doses oflGF-I to be effective.
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Clinical Relevance
This study demonstrates the feasibilty of using a simultaneous growth factor
delivery system and scaffold to support cartilage tissue growth. While the support of
tissue growth must be demonstrated, this study did not assess the use of this method for
cartilage repair, the ultimate goal of tissue engineering. Currently, the only clinically
approved procedure for cartilage repair is autologous chondrocyte transplantation
involving the expansion and delivery of autologous chondrocytes to the defect and
securing the cells with a periosteal graft. 138
139 This cell-based repair technology has
demonstrated variable results, and has shown the development of fibrocartilage in some
cases.
140 141 Although this is the only clinically approved method for cartilage repair, the
literature expounds upon numerous applications for repair using tissue engineering
methods with both chondrocytes and polymer scaffolds.
The expression of fibrocartilage can lead to mechanical instability, and therefore
it is crucial that a clinically relevant cartilage tissue engineering method produces tissue
with solid mechanical properties. One ofthe shortcomings of the work presented in these
studies is a lack of understanding of such mechanical properties that would give an
indication ofthe tissue s ability to distribute stress and bear weight. Because tyical
increases in GAG and collagen matrix have also correlated to substantial increases in
various modulus parameters ofthe tissue/l
32; 164 we would expect that the increases in
GAG and collagen in these studies would translate into higher compressive or tensile
moduli in cartilage formed with 50 kDa polymer or optimal doses oflGF-I. However
the clinical relevance and comparison of engineered cartilage to the compressive and
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tensile properties of native cartilage tissue necessitate mechanical testing of cartilage
formed using PLG micro spheres.
In addition to the indication of tissue fuction by mechanical assessment, cartilage
structure and organization also warrants characterization for a valid cartilage tissue
engineering model. Cartilage tissue is a multi-layered tissue with superficial, middle and
deep zones. Chondrocytes within these different zones exhibit different metabolic
activities that maintain mechanical fuctions specific to that zone. For example
chondrocytes of the superficial zone, the region specialized for stress distribution and
joint lubrication, secrete GAG at relatively low rates 142 143 and produce lubrication
proteins such as superficial zone protein. 144 Deeper layers exhbit increased GAG
content,142 as one of the roles in these zones is to provide resistance against compressive
stresses.
The feasibility of developing stratified cartilage is supported by the fact that three-
dimensional cultue of chondrocytes from different zones maintain the specific metabolic
. .. 
142 145 actIvItIes 0 t e zona popu atlOn an pre Immary euorts to regenerate zona
organization in articular cartilage tissue have been attempted. In one instance, constructs
were seeded with ARC cultured chondrocytes from the superficial zone on top of ARC
cultured chondrocytes from the middle zone chondrocytes. 146 In the second study, zonal
chondrocytes were incorporated into separate layers using a photopolymerizing
hydrogel.29 No cross-contamination between the layers was observed upon construct
harvest in either study, and the tissues exhibited similarity to native cartilage tissue
including gradients of proteoglycan accumulation or secretion of superficial zone protein
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mainly from the superficial zone chondrocytes. Given these initial attempts , it is
possible to fmd a role for PLG micro spheres in stratified cartilage regeneration, most
likely in a composite scaffold. As cells readily attach to microspheres, specific zonal
populations of chondrocytes could be incubated with micro spheres during the 4 hour
attachment period. Moreover, the encapsulated contents in the micro spheres could be
tailored to induce desired effects of the specific population of chondrocytes. PLG
microspheres with attached chondrocytes could be layered in a mold or could be fuher
encapsulated in another polymer, such as hydrogels like alginate or poly ( ethylene oxide).
As a pre-requisite to clinical trials for any tissue engineering model, the feasibility
for cartilage repair must be demonstrated in a large animal model. Typically, initial
studies involve proof of principle using in vitro culture or in vivo, subcutaneous
evaluation.147 Subcutaneous evaluation has most often been demonstrated in small
animals such as mice or rats 37 but larger animals such as the ovine model have also
been used.2 37 Subcutaneous culture of cartilage constructs evaluates the growth
capabilities of the tissue and allows for initial determination of tissue properties such as
matrix accumulation, but does not assess the ability of the method to repair a defect.
Some studies, however, have determined the ability of specific cartilage regeneration
methods to repair defects in large animal models, most notably in canine or equine.
141
Repair in these defects are not only judged on similarities between matrix content and
mechanical properties of the engineered tissue and native cartilage tissue, but also the
importance of engineered tissue integration with endogenous tissue must be reconciled.
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The current study evaluated a novel cartilage tissue engineering method using a
simultaneous scaffold and growth factor delivery vehicle , demonstrating proof of
principle and identifying specific polymer and scaffold characteristics that can lead to
enhanced cartilage repair. A consequent follow-up to this study would include the
evaluation of this cartilage tissue engineering method in a large animal model, with
specific attention to tissue repair, including integration of the engineered/endogenous
cartilage interface , evaluation of matrix synthesis and production, and determination of
mechanical and weight bearing properties.
Significance
In a field such as tissue engineering, understanding basic interactions in the tissue
engineering design wil build a foundation for subsequent studies. There are multiple
facets to the significance of this work including understanding the contribution of
polymer and scaffold to cartilage growth and developing a novel, growth factor delivery
scaffold for cartilage tissue engineering. Both of these advances suggest methods to
enhance cartilage tissue development and may have potential for cartilage repair.
A first novelty of the work presented in this thesis demonstrates initial attempts at
understanding the effects of the polymer scaffold on tissue regeneration. To date, there
has been relatively little work has involved an understanding of pointed changes in the
polymer or scaffold and the effect on tissue formation. However, preliminary research
has suggested that polymer tye and pH can affect cartilage tissue engineering.
79,155
Specifically, fewer chondrocytes attached to PLA versus PGA 155 and increasing the ratio
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ofPLA in a PLAlGA co-polymer decreases chondrocyte attachment.79 Similarly, drops
in pH led to inhibition of matrix assembly. 
50 In contrast
, the work provided in this thesis
marks the first broad range analysis of multiple polymer and scaffold properties that
inuence cartilage tissue growth. Most notably, using increased molecular weight
micro spheres in tissue formation generates cartilage with increased ECM and tissue mass
while release ofMg(OH)2 inhibited matrix and mass accumulation (Chapters n and il).
Although we have evaluated polymer and scaffold properties and the effects on
tissue formation, we have only evaluated parameters for PLG. As there are multiple
tyes of scaffolds used for cartilage tissue engineering, it wil be important to understand
which properties wil enhance cartilage formation in other polymers , such as agarose
alginate , fibrin, collagen, PGA, PLA, chitosan or other polymers. In addition, this study
assessed a limited number of variables that affect tissue formation. It would be important
to further investigate how molecular weight enhances tissue formation (Chapters nand
II by evaluating a range of polymer molecular weights and assessing a variety of
parameters including integrin expression and cell adhesion. Simlarly, it is important to
assess potential reasons for magnesium hydroxide inibition of matrix and tissue growth
(Chapters n and 11; specifically, important avenues of exploration would include
analyzing a range of buffer loads that provides an effective buffer without cellular
toxicity or assessing various, physiological buffers such as HEPES or PBS.
A second novelty arising from this work focused on a scaffold with criteria to
provide for cell attachment and tissue support, as well as growth factor delivery. The
importance of this system is non-trivial and can be understood from the drawbacks of
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current technques. First, a dichotomy exists in scaffold properties and invasiveness of
the repair procedure. PLG tye polymer chains can be easily regulated by controlling
factors that affect degradation rate include capping the polymer, adding a buffer to the
microsphere, or changing properties like molecular weight, microsphere size , porosity, or
pore size (ref. 23 , Chapter II and il). Additionally, these polymers are often shaped and
require surgical implantation. In contrast, polymers such as alginate or collagen have
fewer factors that can be changed to infuence scaffold properties, but the injectability of
these materials make them advantageous for non-invasive procedures.
In our work, we have chosen to utilize PLG microspheres , which offer both an
ease of manipulation of polymer properties and miimization of invasiveness due to the
small, spherical nature of PLG microspheres. Chondrocytes and micro spheres can be
injected in vivo or molded in vitro (Chapters II-V). Moreover, chondrocytes attach to
PLG micro spheres (Appendix A), PLG microspheres support tissue growth (Chapters 11-
V), and PLG microsphere properties can be changed to inuence tissue formation
(Chapters II-V).
Another facet overcome by PLG micro spheres is the limitation of growth factor
half-life when added by exogenous delivery. The ProLease fabrication process of PLG
micro spheres with encapsulated protein has demonstrated almost 99% retention of
protein stability and activity,89 and in this study we have demonstrated effective release
oflGF'-I out to 8 weeks (Chapter IV) with around 70% total release oflGF- I after 8
weeks (Chapter V). Moreover, we have demonstrated that controlled release oflGF-I in
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combination with high molecular weight micro spheres can be used to further enhance
cartilage formation (Chapters IV and V).
Although not determined in this study, it is likely that PLG microspheres can be
used to deliver multiple growth factors. It has been shown that growth factors , such as
TGF- and IGF- , have synergistic effects on tissue formation.25 Because the polymer
properties of PLG micro spheres can be easily changed to affect degradation rate, it is
likely that our system could utilize two sets of PLG micro spheres with the same
degradation times to release growth factors at the same rate for synergistic actions, or by
using micro spheres with different degradation times , one growth factor could be released
prior to a second. Further, it would be important to understand how changes in polymer
and scaffold parameters affected protein release, which was not in the scope of this study.
Similar synergy has been demonstrated with mechanical stimulation and
exogenous IGF-I addition. 168 169 Although not the focus ofthis study, it would be
important to understand synergistic effects of mechanical stimulation, such as
compression or fluid flow, with controlled release oflGF-I to make specific comparison
to the synergy of exogenous delivered IGF-I and mechanical stimulation.
In general , our study has provided specific and novel contributions to tissue
engineering. We have developed a novel polymer scaffold with simultaneous growth
factor release that overcomes the limitations of invasive procedures and protein half-life
two important factors in the tissue engineering field. Moreover, we have demonstrated
that the polymer scaffold does infuence tissue regeneration. Although there are
limitations to our studies , namely a more thorough investigation of ranges in specific
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polymer properties (i.e. a range of molecular weight) that could further enhance of tissue
growth, the level of regulation (gene, protein, or matrix assembly) at which the polymer
influences tissue regeneration, and control of this system to incorporate synergistic
factors (additional growth factors or mechanical stimulation), this work provides a
foundation for future directions to understand the critical role of the polymer scaffold in
cartilage tissue engineering.
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APPENDIX A
CARTILAGE ENGINERED WITH PLG MICROSPHERES EXHffIT
SIMARTIES TO NATIV CARTILAGE: A LOOK AT CELL
ATTACHMENT AN SPACING
Introduction
Cartilage tissue is uniquely structured with a high matrix to cell ratio, and thus the
low cell density, less than 10% of the overall tissue volume, does not promote the
formation of cell-to-cell contacts tyically seen in other tissues. In contrast
chondrocytes attach to and are thus embedded in a dense network of ECM molecules, for
example, collagen tye IT, fibronectin, and hyaluronan. The attachment of chondrocytes
to ECM molecules enables cross-talk and signaling within the tissue, which respond to
stimuli such as growth factors and mechanical loading. 
8 Thus
, the issues of cell spacing
and chondrocyte attachment in engineered cartilage must be of primary focus.
The importance of cellular attachment to the synthetic polymers has been well
established 148 149 and variations in polymers can affect cell attachment. For example
polymer properties such as hydrophobicity/hydrophilicity can impact cell adhesion, as
hydrophilic polymers enhance cell attachment, while hydrophobic polymers decrease
cellattachment. 150 151 In addition, manufactued attachment motifs such as the peptide
RGD can faciltate attachment. 152 153 Alginate is a polymer that does not inerently
faciltate cell adhesion, as this polysaccharide does not provide attachment for
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mammalian cells and its negative charge electrostatically repels protein adsorption.
152
However, modifying alginate to include the RGD peptide enables cells to attach and
spread in alginate hydrogels. 155
In contrast, attachment of chondrocytes to unmodified PLG scaffolds has been
demonstrated without the need for such polymeric modifications and adhesion has been
demonstrated for PLG scaffolds of varying shapes, including fibers and films
155
Although adhesion of chondrocytes to PLG microspheres has not been demonstrated, the
feasibility of chondrocyte attachment to minute shapes has been demonstrated for other
polymer tyes, including microparticles composed of collagen type I or dextran.
Because chondrocytes have been shown to attach to both PLG tye polymers and
minute sized non-PLG polymers , such as microparticles, this suggests that chondrocytes
wil attach to PLG microspheres. Thus, the goal of the studies presented in this appendix
was to determine whether chondrocytes attached to PLG microspheres, and subsequently
to determie the cell spacing in cartilage tissue engineered with only chondrocytes or
with chondrocytes and PLG microspheres.
Materials and Methods
Cell Culture
Chondrocytes were isolated from the articular cartilage of calf gleno-humeral joints
of 2,. 10 day old calves (Research 87, Hopkinton, MA) using 0.3% tye n collagenase
(Worthington), as previously described. After 16 hr of collagenase treatment at 37
isolated chondrocytes were filtered through a 180 m filter to remove any undigested
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cartilage particles , washed several times with PBS , and cells were resuspended in Ham
F12 media supplemented with 1 % ascorbic acid and 10% FBS.
Microsphere Preparation
PLG was obtained form Alkermes, Inc. PLG micro spheres were fabricated using the
ProLease(S process. Briefly, PLG polymer (50:50 lactide:glycolide , uncapped (-COOH),
Mw- l0 kDa) was dissolved in methylene chloride and atomized over a bed of liquid
nitrogen layered on top of frozen ethanol. The temperature of the system was then
maintained at - C to allow for nitrogen evaporation and removal of methylene chloride
into the ethanol phase (microsphere curing). The resulting micro spheres were filtered
and then lyophilzed to remove residual ethanol , and fmally sieved to obtain
micro spheres with an average diameter of35 
Attachment Kinetics
PLG micro spheres were suspended at 3.6 mg microsphere/ml of 0.
carboxymethyl cellulose (Sigma Chemical Company, St. Louis, MO) in F- 12 media and
mixed with lx10 chondrocytes/ml at 37 C. Samples (1 ml) were removed at 0 , 2 , 4 , and
16 hr and separated on a Histopaque- l 077 density gradient (Sigma Chemical Company)
by centrifugation for 5 min at 5000 rpm. DNA content of the top (unattached) and bottom
(attached) fractions were assayed using the Hoechst 33285 Dye Method, as described
(Ki 1988). Briefly, Hoechst 33258 dye (Sigma Chemical Company) was diluted
1:10000 in TEN buffer (Tris-EDTA-Sodium Chloride) to make the dye stock, and 2 ml of
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Hoechst dye stock was added to 50 f.l of each gradient fraction. Fluorescence was read at
358/458 nm. Calf thymus genomic DNA (Sigma Chemical Company) was used as a
standard.
Culture Conditions and Implantation
Chondrocytes, at a density of 80 x 10 cells/mL, were mixed with an equal volume of
PLG microspheres , at a concentration of 64 mg/mL. The microsphere-chondrocyte
suspension was incubated for 4 hr at 37 C in a shaker incubator to allow for chondrocyte
attachment to the microspheres.
Chondrocyte, microsphere, and chondrocyte-microsphere suspensions were injected
into the subcutaneous space ofthe dorsum of nude mice using an 18-gauge needle. Each
injection contained 20 x 10 cells and/or 16 mg of micro spheres in 500 p,L ofF12 media.
Sample Analysis
All animal procedures were performed under the guidelines of the Institutional
Animal Care and Use Committee ofthe University of Massachusetts Medical School.
Mice were sacrificed at 1 , 2 , 4 , 6 , and 8 weeks by anesthesia overdose and samples were
ftrvested from cell alone and chondrocyte-microsphere samples. No tissue samples
could be harvested from microsphere alone injections, as there was no tissue formation at
the site of injection.
Upon harvest, the fibrous capsule was removed from each sample, and the tissue was
either processed for bulk frozen fracture scaning electron microscopy, as described
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below, or fixed in 10% formalin, embedded in paraffm, and sectioned. Sections were
stained with safranin-
Scanning Electron Microscopy
PLG micro spheres were suspended at 3.6 mg microsphere/ml of 0.
carboxymethyl cellulose in F- 12 media and mixed with lxl0 chondrocytes/ml at 37 
Samples (1 ml) were removed at 0 , 2 , 4 , and 16 hr and were pipetted onto SEM slides
covered with Tissue Tack (Sigma Chemical Company). Samples were fixed in 2.
glutaraldehyde overnight at 4 , and subsequently dehydrated in a graded series of
ethanol concentrations up to 95% ethanol. Slides were sputter coated with approximately
10 nm Au/d and examined on an ETEC Autoscan Scanning Electron Microscope
(Perkin Elmer, Wellesley, MA) at 20 Kv.
Alternatively, cartilage tissue engineered from chondrocytes alone or
chondrocytes and micro spheres was harvested after 1 week of in vivo subcutaneous
incubation and was subjected to bulk frozen fracture according to a protocol by
Hendri6ks and Hadley. Is7 As described, tissue samples were fixed in 2.
glutaraldehyde overnight at 4 , and subsequently dehydrated in a graded series of
ethanol concentrations up to 95% ethanol. The partially dehydrated tissue was then
quickly immersed in liquid nitrogen until the boiling ceased, placed on a pre-cooled steel
block, and fractured using a cooled knife. The fractured pieces were collected, thawed in
100% ethanol , and critical point dried in a C02 CPD system. Once dried, the pieces were
mounted on aluminum stubs with silver conductive paste and sputter coated with
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approximately 10 nm Au/d and examied on an ETEC Autoscan Scanning Electron
Microscope at 20 Kv.
Histomorphometr
The internuclear distance between cells (n=lO OOO) was measured using Scion Image
Softare (Scion Corporation, Frederick, MD) (Figure 30a) in cartilage engineered from
only chondrocytes and from cells and microspheres at 2 , 4 , or 8 weeks , as well as native
cartilage tissue. Distances were averaged, values were pooled to form a histogram chart
and evaluated for each time point (Figure 30b).
Results
Chondrocytes bound to PLG micro spheres as evidenced by SEM (data not
shown) and biochemical analysis (Figure 31). Chondrocyte attachment was observed by
SEM at 2 hours (not shown), and a time constant ('t) of approximately 5 hours was
calculated from the attachment kinetic curve (Figure 31). Chondrocytes exhibited first
order binding kinetics with PLG micro spheres with a maximum of 30% attachment to
microspheres (Figure 31).
Chondrocyte attachment within engineered cartilage was also assessed using
SEM. After 1 week, bulk frozen fracture samples from cartilage formed with
chondrocytes and micro spheres indicated a microsphere network that was connected by
chondrocytes and matrix tissue (Figure 32A). Chondrocytes appeared to contour the
curature of the microsphere but retained the normal spherical phenotye (Figure 32B),
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and evidence of attachment was indicated by processes projecting from the chondrocyte
that contacted the surface ofthe microsphere (Figure 32C). Cartilage formed with
chondrocytes and micro spheres generated tissue that maintained its structural integrity
and did not show evidence of fibrous tissue. In contrast, cartilage formed using cells
alone indicated cracks in the tissue that separated the cartilage layer from more fibrous
tissue (Figure 32D).
The internuclear distance of chondrocytes was measured in tissue generated from
chondrocytes and micro spheres and chondrocytes alone. At weeks 2 and 4 , cells spacing
was compact in all samples analyzed, and internuclear distances were similar for cartilage
formed from cells and micro spheres and that formed from only chondrocytes. After 8
weeks, the internuclear distance between chondrocytes increased in all samples, but
cartilage engineered from cells and micro spheres exhibited a significantly higher spacing
of 28 JU as compared to a 24 j.m spacing seen in cartilage formed from only
chondrocytes (p-OO.OOOl) (Figure 33A).
Total cell densities could be calculated from spatial distances in these samples.
When analyzed as such, cell densities at weeks 2 and 4 indicated little variation between
the groups at cell densities of 80-85 x10 cells/ml. However, after 8 weeks, cell densities
were decreased in all samples, but cartilage formed with cells and micro spheres had
significantly lower cell densities (45 x 10 cells/ml) than cartilage formed with
chondrocytes alone (75 x 10 cells/ml). Moreover, cartilage generated from cells and
micro spheres exhibited cell numbers that were more similar to native cartilage values
(Figure 33B).
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Discussion
As the goal of cartilage tissue engineering is to form tissue with close similarities
to native cartilage tissue, cell attachment to the polymer scaffold and subsequent and
appropriate cell spacing is necessary. These adhesion parameters have been studied for
scaffolds made from PLG in various forms 155 but these characteristics have not been
determined for PLG microspheres. Thus, this study documented both the attachment
kinetics of bovine articular chondrocytes to PLG microspheres and the changes in cellular
spacing with time in engineered cartilage tissue.
Cell attachment to the polymer scaffold is vital to engineering of new tissue , 148
and consequently, the first goal in this study was to determine the characteristics of
adhesion to PLG microspheres. SEM indicated chondrocyte attachment as early as 2
weeks , and kinetics demonstrated chondrocyte attachment to PLG micro spheres
increased over the first 12 hours, with an adhesion time constant of 4-5 hours. In
addition, the total amount of chondrocytes that adhered to PLG micro spheres was 30% of
the total seeded chondrocytes. The percentage of cells adhering to PLG microspheres
was consistent with other attachment studies that indicated chondrocyte attachment to
PLA/GA composite scaffolds at 27%.79 In addition to adhesion kinetics , the appearance
of cells has also been used as an attachment indicator, characterized by cell spreading and
protrusion of processes that attach to substrates. 152 154 In this study, chondrocytes clearly
maintained their rounded morphology in cartilage formed with chondrocytes alone (data
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not shown) or chondrocytes and microspheres (Figure 32B), yet cellular processes that
contacted micro spheres were observed in cartilage from cells and microspheres.
Chondrocyte and tissue appearance also gave indications of the overall tissue
integrity. Cartilage tissue from chondrocytes alone indicated evidence of cavities that
were lined with fibrous tissue, but these cavities were not exhibited in cartilage formed
with cells and microspheres. Since the polymer scaffold is known to provide strength
and support to the growing tissue and the chondrocyte protrusions contacted and
appeared to attach to PLG microspheres, it is likely that PLG micro spheres provide a
solid support scaffold for cartilage tissue engineering. Moreover, without this scaffold
support, the structural integrity of the tissue was compromised, which has been shown to
have severe implications in intrinsic cartilage repair, as production of fibrocarilage
generates tissue with inferior biomechanics, tissue breakdown, and osteoarthritis. 158-160
Another important characteristic that the scaffold must lend to the developing
tissue is room to expand. In many tissue engineering designs, matrix deposition has
correlated with polymer degradation 22 and often the scaffold provides a predetermined 3-
dimensional shape and volume for tissue growth and matrix deposition. 26 In contrast, a
predetermied 3-dimensional volume is not available for matrix deposition when PLG
micro spheres are used as a scaffold; rather, tissue volumes exhibited in this study were
attibuted to increases in ECM deposition only. Thus, in tissue engineering applications
withPLG microspheres, micro spheres likely act to maintain additional space for cell
migration and matrix deposition as the tissue forms.
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This theory was evidenced by changes in cell spacing and cell densities as
cartilage formed with or without PLG micro spheres developed over 8 weeks. From
histological analysis presented in chapter IT and il, it appears that chondrocytes are
confmed to areas outside of the microspheres until the microspheres begin to degrade.
Once degradation ensues , chondrocytes may migrate into the degrading microsphere and
deposit matrix. In this study evidence of cell spacing in chondrocyte and microsphere
samples coincided with degradation patterns of the microspheres (data not shown and ref.
23), and thus at time points of2 to 4 weeks, when micro spheres have not yet degraded
internuclear distances in cartilage tissue from both sample sets did not differ. Yet, after 8
weeks , when degradation in micro spheres has occurred, significant variations in
internuclear distances were detected; chondrocytes were more spaced in cartilage formed
using chondrocytes and micro spheres than cartilage formed from chondrocytes alone.
Similarly, differences in cell density between the groups were not apparent after 2 and 4
weeks , but significant differences between the groups after 8 weeks. Over the time of the
study, cell density dropped slightly in cartilage formed with chondrocytes alone, but
maintained a much higher density than that of native cartilage tissue. In contrast, the cell
density in samples formed with cells and PLG micro spheres exhibited cell densities
consistent with those of native cartilage tissue. Other studies have attempted to engineer
carilage tissue by culturing chondrocytes as pellets or in alginate, and while evidence
exists for maintenance of chondrocyte phenotypic markers in these systems
hypercellularity and lack of cell spacing remain problematic. 19 These data and the
data presented in this study suggest that tissue formation with only chondrocytes limits
,."
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the cell spacing and cell density by not providing any additional space for cell migration.
However, in cartilage cultured with PLG micro spheres, the additional space leant by the
PLG microsphere scaffold enables appropriate cell spacing and cell density.
In native cartilage tissue, cells are widely spaced so as not to form cell-cell
contact. Individual chondrocytes are imediately surrounded by a pericellular matrix
which is high in proteoglycans and tye VI collagen. Matrix fuher from the cell
consists of a terrtorial and an interterritorial matrix, the latter forming the majority of the
matrix with collagen tye II and aggrecan.2 A lack of appropriate cells spacing may shift
the balance of matrix constituent concentrations , which in turn would change the
properties of the tissue.
Overall, this study has demonstrated that chondrocytes actively attached to PLG
micro spheres over the first 12 hours of incubation. Moreover, as PLG microsphere
degradation proceeded, spacing of chondrocytes in the engineered cartilage tissue
increased and exhibited cell densities on the level of native cartilage tissue. Taken
together, these data suggest that PLG micro spheres can support cartilage tissue
engineering and maintain space for additional tissue growth.
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Figure 30. Panel A depicts a safranin-O stained cartilage section. Distances between
nuclei were calculated using NIH Scion Image. After all nuclei distances were
calculated, distances were scored for frequency and charted in histograms as depicted in
Panel B.
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Figure 31. Chondrocytes attached to PLG microspheres. Chondrocytes and
micro spheres were incubated over 16 hr. At each time point, unattached cells were
separated from micro spheres and attached cells using a density gradient. Both attached
cell samples and unattached cell samples were detected by fluorescence, as described in
materials and methods. Attachment of chondrocytes was exhibited as early as 2 hr and
increased linearly until 8 hr. After 16 hr, about 30% of cells in the initial cell load had
attached to microspheres.
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Figure 32. Chondrocyte attachment to PLG microspheres can be observed via scanning
electron microscopy. Cartilage formed with cells and microspheres (A-C) or cartilage
formed from cells alone (D) was subjected to bulk frozen fracture and magnified at 50x
(A), 1000x (B), 2000x (C) and 200x (D). Chondrocytes appeared to contour
microspheres (B), indicated by yellow arrowheads, and form attachments via cellular
processes (C), indicated by (p). The fracture process produced both empty pockets
thought to have been occupied by micro spheres (s) and intact micro spheres (is).
Cartilage formed from cells alone exhibited a layer that appeared to have rounded
chondrocytes (cl) and a fibrous-like layer in the center ofthe tissue (ft).
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Figure 33. A. Internuclear distances in cartilage engineered from cells alone or cells and
microspheres were assessed over 8 weeks. No differences in cell spacing were evident at
2 or 4 weeks , but after 8 weeks chondrocytes in cartilage formed from cells and
micro spheres had significantly higher internuclear distances than in cartilage formed
from cells alone (A). Similarly, cell density between the two groups was not different at
2 or 4 weeks, but after 8 weeks , the cell density in cartilage formed with chondrocytes
and micro spheres dropped to native cartilage levels. In contrast, cartilage formed from
cells alone exhibited high cell density after 8 weeks.
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APPENDIX B
GENE TRASFEROFIGF- MAy PROVIE AN ALTERNATIV
DELIVRY METHOD FOR USE IN CARTILAGE TISSUE
ENGINERIG
Introduction
The utilty of growth factors in tissue engineering has been recognized as
advantageous, and many studies have exploited the use of these growth tactors to
maintain cell differentiation or enhance matrix production. Typically, growth factor is
exogenously added to the tissue engineering construct, but is limited by protein half-life
and must be added with each media change ,z4 32 However, novel alternatives to
exogenous delivery are actively being sought, and gene transfer has recently been
evaluated for use in tissue engineering studies.
Cells can be genetically modified to overexpress growth factors by a multitude of
methods. In cartilage tissue engineering genetic modification has mostly been attempted
by transfecting chondrocytes. Chondrocytes transfected with a plasmid containing the
IGF-I gene stimulated a new layer of tissue on cartilage explants70 and formed
carilaginous tissue when seeded in PGA scaffolds. Similarly, transduction of
chondrocytes with adenoviral vectors can effectively be used for gene transfer, and the
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feasibility oftransducing chondrocytes with an adenoviral vector containing the IGF-
gene has been demonstrated. 161 However, recombinant adenovirus with IGF-I has not
been used for tissue engineering applications.
It was the goal of this study to generate an adenoviral construct containg the
IGF-I gene for use in cartilage tissue engineering.
Materials and Methods
Cloning of IGF-I Gene into Adenoviral Vector
The pT7blue3-hIGFI plasmid containg the IGF-I cDNA, a gift from Dr. Dan
Grande, was digested with ClaI overnight at 37 , followed by Hindil (New England
Biolabs) for 3 hr at 37 C to remove the IGF-I gene from the vector. Overhanging ends
were filled using Klenow (New England Biolabs, Beverly, MA) for 1 hr at 37
pShUiT, a gift from Dr. Madelyn Schmidt, was linearized with EcoRV (New England
Biolabs) and 5' phosphates were removed with calf intestinal phosphatase (New England
Biolabs). The filled IGF-I fragment was ligated into the linearized pShUiT in the
presence of polyethylene glycol 6000 (Fisher Scientific, Hampton, NH) with T4 DNA
ligase (New England Biolabs). Potential clones containing the IGF-I gene were screened
using polymerase chain reaction (PCR) with primers IGF forward 5'
CCCAAGCTT A TGGGAAAA TCAGCAGTCTTCCAACCCAA-3' and IGF reverse 5'
CGCGGATCCCTACATCCTCTAGTTTCCTGCACT-
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Transfection of Human Kidney Epithelial Cells with IGF-
Human kidney epithelial (293) cells were transfected with 0
, 1 , or 10 /-g of
pShUiT-IGFI according to the protocol for Lipofectamine Reagent. Briefly, pShUiT-
IGFI DNA was mixed with Opti-MEM I (Gibco , Carlsbad, CA) and Plus Reagent
(Invitrogen Life Technologies, Carlsbad, CA) and incubated at room temperature for 15
min. Lipofectamie Reagent (Invitrogen Life Technologies) was diluted in Opti-MEM I
and 50 /-l diluted lipofectamine was added to each tube of DNA. DNA and lipofectamine
were incubated together for 15 min at room temperature and then transferred to 293 cells
(80% confuent) in a 6 well plate. DNA-lipofectamine was allowed to incubate for 3 hr
at 37 C and then F - 12/D- MEM media was added to each well. Cells were allowed to
recover for 72 hr, after which media was removed for IGF-I detection by ELISA.
IGF-I ELISA
Media was assayed for IGF-I content using the Human IGF-I Quantikine ELISA
kit according to the manufacturers specifications (R&D Systems , Inc, Mineapolis , MN).
IGF-I standards and collected media were incubated on an ELISA plate pre-coated with
mouse monoclonal IGF-I antibody for 2 hr at 4 C. Unbound samples were washed from
plate and the plate was incubated with an IGF-I polyclonal antibody conjugated to
horseradish peroxidase at 4 C. Excess secondary antibody was washed from the plate
and wells were incubated with hydrogen peroxide/chromogen for detection oflGF-
Optical densities were read at 450nm.
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Results
Four clones containing the IGF-I insert were identified by PCR with primers
specific for the 5' and 3' termini of the IGF- I ORF (Figure 34). Repeated attempts to
determine orientation oftheIGF-I ORF by restriction digestion were unsuccessful.
Therefore, each construct was transfected into human kidney epithelial cells. Screening
of supernatants of the transfected cells for the presence of I GF - I at 72 hr post transfection
by ELISA were also unsuccessful.
Discussion
In this study we successfully cloned the IGF-I gene into the pShUiT adenoviral
vector, however, we did not see IGF-I expression in transfected 293 cells. One
possibility for lack oflGF-I expression is that the gene was ligated into pShUiT in
reverse orientation to the vector derived ubiquitin promoter. Similarly, poor transfection
of293 cells with IGF-I DNA could explain the lack oflGF-I expression. Future studies
would need to re-transfect 293 cells or another suitable cell line to obtain effcient
transfection conditions.
The importance of this study provides preliminary techniques for generating an
adenoviral vector that contains the IGF-I gene. Transduction of chondrocytes with
adenoviral vectors could provide an alternative delivery method for adding growth factor
to the tissue engineered construct, and the utility of this method would be advantageous
198
because it offers the potential for genetic transduction in vitro161 or in vivo gene transfer
via direct injection. 162
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Figure 33. pShUiT-IGFI contains the IGF-I gene. The IGF-I ORF was amplified by
PCR from purified plasmid DNA recovered from candidate clones. PCR products were
analyzed by electrophoresis in a 1 % agarose gel and visualized by ethidium bromide
staining. Lane 1. 1 kb Ladder (New England Biolabs); Lane 2. pT7blue3-hIGFI (control
template); Lanes 3-7. pShUiT-IGFI candidate clones.
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